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Supervisory Professor: Wayne D. Newhauser, Ph.D. 
 
Advances in radiotherapy have generated increased interest in comparative studies of treatment 
techniques and their effectiveness.  In this respect, pediatric patients are of specific interest 
because of their sensitivity to radiation induced second cancers.  However, due to the rarity of 
childhood cancers and the long latency of second cancers, large sample sizes are unavailable 
for the epidemiological study of contemporary radiotherapy treatments.  Additionally, when 
specific treatments are considered, such as proton therapy, sample sizes are further reduced due 
to the rareness of such treatments.  We propose a method to improve statistical power in micro 
clinical trials.   Specifically, we use a more biologically relevant quantity, cancer equivalent 
dose (DCE), to estimate risk instead of mean absorbed dose (DMA).  Our objective was to 
demonstrate that when DCE is used fewer subjects are needed for clinical trials.  Thus, we 
compared the impact of DCE vs. DMA on sample size in a virtual clinical trial that estimated risk 
for second cancer (SC) in the thyroid following craniospinal irradiation (CSI) of pediatric 
patients using protons vs. photons.  Dose reconstruction, risk models, and statistical analysis 
were used to evaluate SC risk from therapeutic and stray radiation from CSI for 18 patients.   
Absorbed dose was calculated in two ways: with (1) traditional DMA and (2) with DCE.  DCE and 
DMA values were used to estimate relative risk of SC incidence (RRCE and RRMA, respectively) 
after proton vs. photon CSI.  Ratios of RR for proton vs. photon CSI (RRRCE and RRRMA) were 
then used in comparative estimations of sample size to determine the minimal number of 
patients needed to maintain 80% statistical power when using DCE vs. DMA.  For all patients, we 
found that protons substantially reduced the risk of developing a second thyroid cancer when 
compared to photon therapy.  Mean RRR values were 0.052±0.014 and 0.087±0.021 for RRRMA 
and RRRCE, respectively.  However, we did not find that use of DCE reduced the number of 
patents needed for acceptable statistical power (i.e, 80%).  In fact, when considerations were 
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made for RRR values that met equipoise requirements and the need for descriptive statistics, the 
minimum number of patients needed for a micro-clinical trial increased from 17 using DMA to 
37 using DCE.  Subsequent analyses revealed that for our sample, the most influential factor in 
determining variations in sample size was the experimental standard deviation of estimates for 
RRR across the patient sample.  Additionally, because the relative uncertainty in dose from 
proton CSI was so much larger (on the order of 2000 times larger) than the other uncertainty 
terms, it dominated the uncertainty in RRR.  Thus, we found that use of corrections for cell 
sterilization, in the form of DCE, may be an important and underappreciated consideration in the 
design of clinical trials and radio-epidemiological studies.  In addition, the accurate application 
of cell sterilization to thyroid dose was sensitive to variations in absorbed dose, especially for 
proton CSI, which may stem from errors in patient positioning, range calculation, and other 
aspects of treatment planning and delivery.   
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Chapter One 
 
1 Introduction and background 
1.1   General 
In recent decades, there has been notable improvement in the survival of children 
diagnosed with cancer.  Estimates from the SEER program indicate that the overall 5-year 
survival rate for children aged 0-20 increased from 65% during 1978-1990 to 80% during 
1996-2004 (Ries et al. 2006); thus, both the number of survivors and their associated life span 
are increasing.  Reasons for these increases include centralization of care, improvements in 
chemotherapy and surgery, and key advances in radiotherapy.  Radiotherapy is of particular 
interest here because of its vital role in pediatric treatment design (Taylor 1996). 
  While proton therapy is noted for its increased ability to produce conformal dose 
distributions about the tumor, its most notable attribute is its potential to spare healthy tissue.  
Correspondingly, many have speculated that proton therapy carries relatively lower risk for 
secondary malignant neoplasms (SMNs), or second cancers that occur in regions of low levels 
of ionizing radiation.  However, there is justified skepticism in that speculation; in particular, 
there is concern regarding the use of proton radiation therapy because of risk of SMN’s from 
stray neutron irradiation (Hall et al. 2006, Hall et al. 2009; Newhauser et al. 2009a, Newhauser 
et al. 2009b).    Several recent works have investigated stray neutron irradiation in proton 
therapy (Zheng et al. 2007; Fontenot et al. 2008).  These works provided more accurate 
estimations  regarding risks of SMNs after proton therapy. The need for a clear understanding 
of SMN risk is vital and urgent due to the growing numbers of proton therapy centers 
(Sisterson 2005). 
Regardless of the treatment method, ionizing radiation is known to be carcinogenic 
(ICRP 1990; Wrixon 2008), and  SMN risk has been studied epidemiologically for patients 
who received radiation therapy (Howlader et al. 2010).  In addition, epidemiological studies 
have examined the risk of SMNs as a result of childhood cancer survival (Linet et al. 1999; 
Mertens et al. 2001; Neglia et al. 2001; Inskip 2007).  However, in the recent literature there 
have not been reports of epidemiological studies which focus on advanced radiotherapies. 
Several groups have reported on stray neutron contributions to dose in both proton and 
photon modalities (Yan et al. 2002; Kry et al. 2005; Howell et al. 2006; Zheng et al. 2007; 
Fontenot et al. 2008), and case studies have compared and contrasted the dose-related risk of 
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radiation induced SMNs after proton and photon treatments (Miralbell et al. 2002; Schneider et 
al. 2007; Ruben et al. 2008). 
Achieving statistically significant results in an epidemiological study that focuses on 
the use of advanced radiotherapy modalities (such as proton therapy) has been difficult for 
several reasons.  First, childhood cancer is rare; the Surveillance, Epidemiology and End 
Results program of the NCI reported only 12,400 total first cancers per year in the US (Ries et 
al. 1999). Second, the latency associated with second cancers is typically long, e.g., typically 
longer than 5 years for solid tumors (Friedman et al. 2009). Finally, the evolution of 
radiotherapy equipment is so rapid that it is difficult to accrue a statistically significant result 
within the life cycle of one generation of treatment technology. 
 
1.2   Statement of the problem 
Although there is a clear and urgent need to understand the risk of SMNs following the 
use of conventional photon vs. proton radiotherapy in pediatric populations, there is still a 
remarkable paucity of relevant data regarding this subject.  Relatively few children develop 
cancer and even fewer pediatric patients have been treated with proton therapy.  The resulting 
small size of the patient population has thus impeded efforts to accrue a sufficient number of 
patients for epidemiological correlation of cause and effect.  Large sample sizes are typically 
needed for an epidemiological study because dose across organs is averaged using several 
points of calculation across the organ of interest (Stovall et al. 2006); as a result, large 
numbers of patients are needed to offset the large and variable errors in individual dose values.  
Furthermore, because of the rarity of childhood cancers and the long latencies for SMNs, 
epidemiologic investigations are challenging.  Specifically, years or decades may pass before 
enough data are available, by which time the relevance of the results is diminished.  This is of 
particular concern given that children are reported to have six times the sensitivity to radiation 
that adults have (Inskip and Curtis 2007).   
 
1.3   Hypothesis and specific aims 
To overcome the obstacle of small sample sizes, we proposed a method to increase the 
power of a radiation epidemiological study for a given sample size.  Our method modified the 
current practice of using mean absorbed dose with organ-specific SMN risk models by 
incorporating a cell sterilization factor that accounts for confounding factors such as the non-
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linear response of tissue to absorbed dose 20 and non-uniform dose distributions in a specific 
organ.  The hypothesis of this study is that acceptable statistical power (80%) for an 
epidemiological study of secondary cancer incidence following radiation therapy can be 
attained with smaller numbers of patients using “cancer equivalent dose” in place of the 
traditional “mean absorbed dose.” 
To test the hypothesis we conducted a virtual epidemiological study (i.e., a pilot 
simulation study for possible future radio-epidemiological studies) that used “cancer equivalent 
dose” and “mean absorbed dose” to estimate the risk of second cancer incidence of the thyroid 
in survivors treated with craniospinal irradiation (CSI) using proton vs. photon radiotherapies.  
We used data from this study to determine the number of subjects needed for 80% power in our 
study.  To do this, addressed two specific aims: 
Specific Aim 1: Determine the smallest number of subjects needed to achieve 80% power 
when cancer equivalent dose (DCE) vs. mean absorbed dose (DMA) is used in a virtual 
epidemiological study of second cancer in the thyroid following CSI using proton vs. photon 
radiotherapies.  
Specific Aim 2: Estimate the uncertainty associated with calculations of risk of second cancer 
in the thyroid for one representative patient following proton radiotherapy vs. photon 
radiotherapies when cancer equivalent dose (DCE) and mean absorbed dose (DMA) are 
respectively applied. 
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Chapter Two 
2 Methods and materials 
This chapter describes the methods and materials used in this study.  It begins with an 
overview of the virtual clinical trial and its design (2.1).  Next, it presents formalisms for the 
dose models that were used in this work (2.2), namely the mean absorbed (2.2.1) and cancer 
equivalent (2.2.2) dose models.  Then, it details patient selection methods (2.3) and the 
definition of total absorbed dose (2.4).  Descriptions are given on how values for therapeutic 
dose (2.5) and stray dose (2.6) were estimated and extracted for proton CSI (2.6.1) and photon 
CSI (2.6.2), respectively.   After that, it includes a section which details how risk was predicted 
(2.7) using the mean absorbed dose (2.7.1) and cancer equivalent dose (2.7.2).   The chapter 
concludes by describing the methods for estimating statistical power and sample size 
estimations (2.8) and the uncertainty analysis performed for the study (2.9). 
 
2.1 Design of the clinical trial 
We designed a prospective virtual clinical trial to estimate the risk of second cancers in 
the thyroid following childhood CSI using current radiotherapy techniques.  More precisely, (1) 
we used an established risk model to estimate the risk of a second cancers in the thyroid (NRC 
2006), and (2) we used calculated organ and tissue doses.  We used this approach to perform an 
virtual (in-silico) trial in order to overcome the obstacles of small available sample size and the 
5-10 year latency time for thyroid cancer after pediatric exposure (Inskip 2001 and references 
therein).   To study the impact of two current radiotherapy techniques, we defined two arms for 
our trial.  In the first arm, we considered CSI with passively scattered protons in the 160 MeV 
to 200 MeV proton energy interval.  In the second arm we considered CSI with 6 MV photons.  
In both arms CSI was delivered according to the current standards of care (SOC) at our 
institution (details provided in sections 2.5.1 and 2.5.2).  A diagram which illustrates the role of 
the virtual clinical trial within the overall framework of this project follows (Figure 1). 
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Figure 1.  Illustration of the role of the virtual clinical trial in determining sample size 
Two dose models, termed DMA  and DCE, are applied to the virtual clinical trial to determine 
their respective effect on the sample size needed and the power achieved in the trial.  Details 
regarding the dose models follow in section 2.2. 
 
2.2 Definitions of organ dose quantities  
Dose was calculated in two ways: using the traditional quantity of mean absorbed dose, 
DMA, (ICRP 1990) and the quantity of cancer equivalent dose, DCE, (Schneider and Kaser-Hotz 
2005; Schneider et al. 2005).  To ensure that we accounted for biological effects at the location 
in the thyroid where they were most likely occuring, we applied DCE on a voxel by voxel basis.  
Then to reduce the number of varibles between use of DMA vs. DCE, we applied DMA on a voxel 
by voxel basis as well.  Details for DMA vs. DCE follow. 
2.2.1 Mean absorbed dose model 
The mean absorbed dose, DMA, is the mass-weighted average absorbed dose to an 
organ.  It this study it was calculated in the thyroid using 
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∑
∑
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where M is the number of dose voxels in the thyroid1, Di is the dose at the ith voxel, mi is the 
mass at the ith voxel, iρ  is the mass density of tissue at the i
th
 voxel, and Vi is the volume at the 
ith voxel (constant for voxels i - j).  DMA was averaged over each voxel in the thyroid to account 
for potential non-uniformities in absorbed dose and mass density.   
2.2.2 Cancer equivalent dose model 
The cancer equivalent dose, DCE is defined in this study as  
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where M is the number voxels in the thyroid, Di is the absorbed dose at the ith voxel, mi is the 
mass at the ith voxel, iρ  is the mass density of tissue at the ith voxel, Vi is the volume at the ith 
voxel (constant for voxels i - j), and Ci is the cell sterilization factor for ith voxel.  Ci was 
calculated according to 
,
organ iD
i eC
α−
=
     (2.3) 
where αorgan is an organ-specific cell sterilization parameter which we defined following the 
methods of Schneider et al. (2005)  and applied to the absorbed dose  Di.   Similar to DMA, the 
cancer equivalent dose was summed over each voxel in the thyroid to provide a corrected dose, 
or DCE, which allowed for consideration of non-uniformities in absorbed dose, mass density, 
and cell sterilization. 
 
2.3 Patient accrual 
Patient data were collected using the consecutive sampling method (Lunsford and 
Lunsford 1995).  The inclusion criteria for the study include: age (2 - 18 y at treatment), 
treatment at MDACC between 1998 and 2009, treated on protocol (CCGA-9961) or according 
to the prevailing radiotherapy standard of care (SOC) at MDACC, availability of CT images, 
and availability of relevant treatment plans.  The sample was fairly evenly distributed in age 
and sex (Figure 2).   
 
                                                     
1
 ‘M’ is used for the number of dose voxels in the thyroid because ‘N’ is used to represent the number of patients 
in the study.  Because the number of dose voxels in the thyroid is constant for each patient, M will be the same for 
DMA and DCE. 
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Figure 2. Distribution of age and sex within the CSI cohort. 
Male and female patients are plotted for their age at exposure (e).  There are 16 males (2-16 y) 
and 18 females (2-18 y).  The maximum difference between the age-paired male and female 
patients was one year. 
 
For practical purposes, several additional inclusion criteria were used.  In particular, (1) 
patient orientation was required to be supine.  (2) Patient immobilization was required to 
consist of a thermoplastic facemask (AquaplastRTTM, WFR/Aquaplast Corp.) and a standard 
plastic head holder.  (3) Spinal fields in the patient’s treatment plan for proton CSI were 
required to be oriented in the posterior-anterior direction through a standardized table top, and 
finally, (4) to facilitate determination of total dose from proton irradiation (section 2.4), the 
patient’s treatment plan was required to pass a project-specific import/export test of the 
integrity of the electronic data exchange.  More specifically, treatment plans were required to 
successfully export from the clinical radiation treatment planning (RTP) database, import into 
the research database, support edits while in the research RTP database, successfully export 
files containing dose and beam set-up information from the research database into the Monte 
Carlo Proton Radiotherapy Treatment Planning (MCPRTP) system (Newhauser et al. 2007b, 
Newhauser et al. 2008) and after low-statistic Monte Carlo (MC) simulations (for process 
testing only), successfully re-import dose files into the research database for display and 
analysis.   
 
2.4 Total absorbed dose determined with therapeutic and stray radiation 
In this study, we defined total absorbed dose to include absorbed dose from therapeutic 
and stray radiation.  While this definition was used in both arms of the study, there were slight 
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differences in how stray dose was characterized for photon CSI vs. photon CSI.  In this section, 
we briefly summarize those differences and present an overview of the corresponding methods 
for estimating therapeutic dose and stray dose for proton CSI and photon CSI, respectively. 
Therapeutic dose was defined as the absorbed dose in the volume irradiated by the 
therapeutic beam (inclusive of leakage and scattered radiation).  For both arms of the study, 
therapeutic dose was defined as dose within a 50% isodose region as estimated by a 
convolution superposition algorithm in a commercially available treatment planning system 
(TPS) (Eclipse version 8.6, Varian Medical Systems, Palo Alto, CA).   
Stray dose was defined as the absorbed dose from radiation which was created as a 
consequence of delivering the therapeutic beam.  Consequently, the methods for estimating 
stray dose differed for proton CSI and photon CSI, respectively.   For proton CSI, stray dose 
was predominated by neutrons generated in the patient and emanating from the treatment unit 
(Agosteo et al. 1998; Yan et al. 2002; Taddei et al. 2008, 2009).  Because the TPS did not 
include neutrons in its estimation of stray absorbed dose, we used alternate methods of dose 
estimation.  Specifically, Monte Carlo (MC) simulations were used to determine absorbed dose 
from the stray neutrons (details provided in section 2.6.1).  In contrast, in the photon arm of our 
study, the source of stray dose was leakage and scattered photon radiation emanating from the 
treatment unit.  Thus, based on the results from Howell et al. (2010a, 2010b) and treatment 
plans from this work, we determined that the TPS could be used to accurately estimate 
absorbed dose from stray radiation in our study (details provided in section 2.6.2).   
 
Table 1. Summary of the methods used to estimate therapeutic and stray dose 
The methods used to estimate therapeutic and stray dose are listed.  ‘TPS’ indicates that 
absorbed dose was estimated using the pencil beam algorithm in the TPS, and ‘MC’ indicates 
absorbed dose was estimated from Monte Carlo simulations.  The parentheses contain section 
numbers where more detail can be found.    
 
 
 
 
 
 
 
 
 Therapeutic Absorbed Dose Stray Absorbed Dose 
Proton CSI TPS (2.5.1) MC (2.6.1) 
Photon CSI TPS (2.5.2) TPS (2.6.2) 
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2.5 Therapeutic dose  
2.5.1 Treatment plans 
In both the proton and photon arms of the study, therapeutic dose was determined for 
patient-specific treatment plans which were generated using the clinical TPS.  For all patients, 
proton treatment plans pre-existed in the clinical database.  These plans corresponded to the 
patient’s original clinical treatment; however in most cases, due to import/export limitations of 
the treatment planning system (TPS), modifications to the pre-existing treatment plans were 
necessary. The modified plans were reviewed by a physician and approved once it was 
determined that they met the prevailing clinical SOC for the proton arm of the study.   In 
contrast, clinical treatment plans did not exist for the photon arm of the study, as a result, 
photon treatment plans were developed specifically for this study (using the methods described 
in section 2.5.2).  Similar to the proton treatment plans, the photon treatment plans were 
approved by the same physician based on the prevailing clinical SOC for photon CSI at our 
institution. 
2.5.1.1 Treatment plans for proton CSI 
 Treatment plans for therapeutic dose from proton CSI were designed according to the 
prevailing SOC at our institution, which uses a three to five field approach (Figure 3).   
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Figure 3.  Illustration of the dose distribution for proton CSI. 
Typically two fields are used to treat the cranium while one to three fields are used to treat the 
spinal axis. (a) The larger patient was 16 y-old female, patient 7, which required three spinal 
fields to cover spinal axis. (b) The smaller patient was 4 y-old male, patient 12, which required 
only one spinal field to cover spinal axis.  (c) Isodose scale for both treatment plans.  From 
Howell et al. (in preparation). 
 
These fields were prescribed to deliver a therapeutic dose of 23.4 Gy (RBE) in 13 1.8 Gy 
(RBE) fractions.  Units of Gy (RBE) were used in accordance with our clinic’s SOC which 
presumes that proton beams have a higher relative biological effectiveness (RBE) than photon 
beams 22.   Thus, the absorbed dose was estimated, following the ICRU method, as 
     DRBE[Gy (RBE)] =  Dabsorbed[Gy]×  RBE   (2.4) 
where the RBE value is taken as 1.1 and Dabsorbed is absorbed dose in Gy.    
 A detailed methodology for how the proton treatment fields were designed was 
provided by Howell et al. (in preparation).  The methodology is briefly outlined here. (1) Two 
posterior oblique cranial fields (LPO and RPO) were matched to the most superior spinal field.  
(2) Spinal fields consisted of two to three posterior fields, depending on the patient’s length, 
which were matched at their superior/inferior junctions, as appropriate, so that the combined 
spinal field extended from the posterior edge of the cranial fields through the thecal sac.  (3) 
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The posterior-anterior extent of the spinal fields varied with patient age.  More specifically, in 
patients younger than 15 years, the spinal fields were designed to cover the entire vertebral 
body (Figure 4a). In patients older than 15 years, spinal fields extended anterior to the vertebral 
canal by only 3 to 6 mm, such that only the posterior-most 3 to 6 mm of the vertebral body 
were included in the spinal field (Figure 4b).   By reducing dose to the vertebral body, dose to 
bone marrow was reduced.  This allowed for higher chemotherapy doses in older patients 
(Howell et al. in preparation).   
    
Figure 4.  Illustration of the age-specific proton beam range for spinal fields. 
Axial view of the isodose lines for a prescribed dose of 2340 cGy (RBE) with proton CSI. (a) 
Spinal fields for a 2 y-old patient covered the entire vertebral body.  (b) Spinal fields for a 15 y-
old patient covered the posterior 6 mm of the vertebral body. (c) Isodose scale for both images. 
 
To reduce the MC simulation time, proton treatment plans utilized in this study did not include 
junction shifts.  While this practice differs from the current SOC for proton CSI, i.e., a 
composite treatment plan which includes three sub-plans with different locations for field 
junctions, the plans in this study were re-optimized to achieve comparable homogeneity with 
plans containing junction shifts.  These plans were then approved by a board-certified radiation 
pediatric oncologist.  Additional documentation is available elsewhere (Giebeler 2009).   
2.5.1.2 Treatment plans for photon CSI 
Treatment plans for photon CSI utilized the same CT data, or patient density 
information, as the proton treatment plans and were developed according to our institution’s 
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prevailing SOC.  More precisely, the photon CSI plans utilized 6 MV fields with a field-in-
field (FIF) technique to deliver a prescribed dose of 23.4 Gy using 13 fractions of 1.8 Gy 
apiece.  The FIF technique was adapted from its original form (Yom et al 2007) for use with 
the TPS used in this study by Howell et al. (in preparation).  In brief, a typical plan consisted of 
3 junction shifted sub-plans.  Junctions were shifted by 1 cm between sub-plans to reproduce 
clinically relevant hot or cold regions at junction locations.  Each sub-plan used two laterally 
opposed brain fields and one to two spine fields.  The spine fields were matched to the brain 
fields and each other at depth, i.e., in soft tissue just posterior to the spinal canal).  The location 
of the match point between fields, or junction location, was varied between sub-plans to avoid 
hot spots.  Additionally, to homogenize dose in high dose areas, the brain and spine fields in 
each sub-plan were optimized using three to five sub-fields with lower weights.  The resulting 
dose distribution for a 6 MV photon plan for CSI is shown in Figure 5. 
   
Figure 5.  Illustration of the FIF treatment technique for 6 MV photon CSI 
(a)  The larger patient was 16 y-old female, patient 7, which required two spinal fields to cover 
the spinal axis. (b) The smaller patient was 4 y-old male, patient 12, which required only one 
spinal field to cover spinal axis. (c) Isodose scale for both composite treatment plans. From 
Howell et al. (in preparation). 
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2.5.2 Volume-weighted mean therapeutic dose 
To apply DCE and DMA on a voxelized basis within the thyroid, we exported differential 
dose volume histograms (dDVH)s from the TPS into a spreadsheet for each patient in the 
study.  The dDVHs reported the volume (cc) of the thyroid which received specific increments 
of dose (cGy RBE).  The increments of dose were termed dose-bins; they spanned the 
minimum dose in the thyroid to the maximum dose in the thyroid.  As a result, each patient’s 
dDVH provided (1) a patient-specific number of dose-bins and (2) the volume (cc) of thyroid 
which received the corresponding dose to each dose-bin.  To determine the mean absorbed 
therapeutic dose across the thyroid using DMA we utilized equation 2.2 but in the following 
form2 where ρi is assumed to be constant because the thyroid contains only glandular tissue (as 
opposed to bone or air pockets), 
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where O is the number of dose-bins in the thyroid, Di is the therapeutic dose (Gy) at the ith 
dose-bin, mi is the mass at the ith dose-bin, iρ  is the mass density of tissue at the i
th
 dose-bin, 
and Vi  is the volume of the ith dose-bin (cc). VT is total the volume of the thyroid (cc).  
Similarly for DCE, the cancer equivalent dose across the thyroid was determined using,  
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where Ci is the cell sterilization  factor (equation 2.3) for the ith dose-bin and N, Di, mi, iρ , Vi, 
and  VT  are as defined for equation 2.5. 
On average, the width of the dose-bins in our dDVHs was 1 cGy. However in select 
cases, bins were re-set to 0.05 cGy before export to avoid errors associated with under-binning 
of the data.  More precisely stated, if the mean absorbed dose in the thyroid was less than 1 
cGy smaller bins were needed for accurate resolution of the volume specific dose (Figure 6), 
                                                     
2
 To transition to equation 2.5 from equation 2.2, we applied the density equation, ρ = m/V to the numerator and 
denominator of equation 2.2 and recognized that the values for m were approximately constant in the thyroid.  
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and based on accuracy tests for dDVH output, the width of the smaller dose bins was set to 
0.05 cGy.   
 
Figure 6. Illustration of dDVH with dose less than 1 cGy 
The dDVH for a select case where re-binning of the data from 1 cGy dose bins to 0.05 cGy 
dose bins was needed.  Without re-binning, the volume weighted mean absorbed dose was 
estimated at 1 cGy as opposed to 0.2 cGy as shown. 
 
 
2.6 Stray Dose 
2.6.1 Stray dose from proton CSI 
Stray dose from proton CSI was calculated using methods from previous works on stray 
dose from neutrons.  Detailed descriptions of how stray dose data is calculated and how it 
contributes to therapeutic dose in pediatric CSI were described previously (Taddei et al. 2010, 
Taddei et al. 2008, Taddei et al. 2009; Newhauser et al. 2009a).  However, for convenience a 
review of that process follows.   
In brief, estimates for absorbed dose from stray neutrons were calculated for each 
patient using the Monte Carlo Proton Radiotherapy Treatment Planning (MCPRTP) code 
(Newhauser et al. 2007, 2008) which runs the Monte Carlo code, MCNPX (Monte Carlo N 
Particle eXtended) (Waters et al. 2002, Pelowitz et al.  2005). Input into MCPRTP included 
patient specific parameters which were specified by the patients’ proton CSI treatment plans 
(e.g., the CT data set, apertures, range compensators, and beam line parameters), and output 
from MCPRTP was returned in the form of individual dose files for each cranial and spinal 
treatment field.  After the dose files were generated, they were manually imported into the 
clinical TPS for evaluation.   The evaluation process included visual inspection of the imported 
dose relative to the patient anatomy and a re-scaling of the imported dose to clinically relevant 
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levels.  Re-scaling was necessitated due to differences in how absorbed dose was normalized 
between MCPRTP and the clinical TPS.  More specifically, MCPRTP uses monitor units (MU) 
to scale its output into units of Gy.  However, because the treatment plans in this study were 
not clinically delivered, MU’s were not assigned to the treatment fields.  As a result field-
specific MU values were taken from each patient’s original clinical treatment and entered into 
MCPRTP.  To address the resulting potential for differences in reported dose, we developed a 
method which utilized field specific scaling volumes (SV)’s (Figure 7).  
 
 
Figure 7. Illustration of scaling volumes (SV)’s. 
SV’s shown for the brain, upper spine, mid spine, and lower spine fields.  The red arrows 
indicate gaps between the contours which correspond to field edges or regions of high dose 
heterogeneity. 
 
The SV’s were designed to correspond to regions of uniform dose.  As a result, they did 
not include field junctions or extend to the full range of their respective treatment fields.  Once 
the SV’s were defined, estimated values of mean dose in the SV from MCPRTP and the 
clinical TPS were compared on a field by field basis using,  
SV ,MC
SVTPS,
D
D
S j = ,     (2.7) 
16 
 
where Sj is the field specific scaling factor for dose generated by the MCPRTP vs. clinical TPS 
in the jth field, i.e., j =  1,2,3,…,p.  SVTPS,D is the mean dose across SV as reported by the TPS 
and SV ,MCD is the mean dose across the SV as reported by MCPRTP.  Once Sj was determined 
for each field, we estimated the mean equivalent dose in our organ of interest, the thyroid.  This 
was done using  
∑
=
=
M
1j
jHH ,   (2.8) 
where equivalent dose in the thyroid, H, was determined on a field-by-field basis for fields 1 
through p using,  
    
1.110
TTPS,R DS
w
H jj ⋅⋅= ,     (2.9) 
where TTPS,D is the mean absorbed dose calculated by MCPRTP in the thyroid in units of cGy, 
10 converts from cGy to mGy because H is in units of mSv,  1.1 converts the absorbed dose 
units from cGy (RBE) to cGy, Sj is defined by Equation 2.7, and Rw is the mean radiation-
weighting factor for neutrons (details in section 2.7).  
 
2.6.2 Stray dose from photon CSI 
  Recent work by Howell et al. (2010a, 2010b) found that the 6MV photon dose 
calculations for this TPS were accurate at doses as low as 5% of the prescribed dose.  In this 
study, for photon CSI, the thyroid was included within the 5% isodose region generated by the 
TPS for all patients in the study (N = 18).  Thus, in the case of photon CSI, the thyroid was 
considered to be an in-field organ, and estimations of total dose by the TPS were considered 
to be accurate (Howell et al. 2010a, Howell et al. 2010b).   
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Figure 8. Location of the thyroid relative to isodose lines  
Sagittal image of the isodose lines for a 4 year-old male (patient #12). The thyroid location 
relative to isodose lines (a) proton CSI and (b) photon CSI are shown. 
 
2.7 Equivalent Dose 
Because our estimations for total absorbed dose (section 2.4) included contributions 
from photon, proton, and neutron irradiation, we utilized the concept of equivalent dose as 
defined by the International Commission on Radiological Protection, ICRP.  The ICRP (ICRP 
1991) defined equivalent dose for a tissue, T, as  
       	     (2.10) 
where DT  is the absorbed dose in a tissue, T,  and  is the mean radiation weighting factor.  
For photon irradiation, the value for  was taken as 1 (ICRP 2003).  Thus for photon 
CSI, the equivalent dose in Sv is, 
   1  	     (2.11) 
where DT is the absorbed dose in Gy in the thyroid3. 
For proton irradiation, we consulted ICRP Publication 103 (2007) which suggests that 
 can be estimated using the mean quality factor, Q , which is averaged over the effective 
interval of LET values for the field.  Thus, equation for the equivalent dose in Sv for the 
thyroid from therapeutic protons becomes, 
       	  	,    (2.12a) 
                                                     
3
 For simplicity, we drop the subscript ‘T’ for all subsequent equation because we considered only one tissue, 
thyroid, in this project.  Thus, all equations following equation 2.11 implicitly describe thyroid tissue only. 
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where Q for therapeutic protons is 1.1 (section 2.5.1.1) and D is defined as in equation 2.7.     
Thus for proton CSI,   
       1.1  	 ,   (2.12b) 
and the equation for the equivalent dose for the thyroid from stray neutrons becomes 
    DwH ×= Rstray ,    (2.14) 
where D is defined as in equation 2.7 and Rw is the energy summed weighting factor for 
neutrons.  We used field specific values for  which were taken from a study by Newhauer et 
al. (2009).    
In brief, Newhauser et al. (2009) performed organ-specific simulations of neutron 
spectral fluence in an anthropomorphic computational phantom which received proton CSI.  
Then they calculated values for  following recommendations in ICRP Publication 92 (2003) 
for cranial, superior spinal and inferior spinal treatment fields.  We averaged their values for 
 across all organs, so in this work,   for the cranial fields, superior spinal field, and 
inferior spinal field were, 7.75, 8.09, and 8.17, respectively.  For the middle spinal field we 
used the average of the superior and inferior spinal fields, 8.13.   
Once Htherapeautic and Hstray were defined, equations 2.14 and 2.12b, the total equivalent 
dose for proton irradiation was defined as,   
                                                  strayctherapeutitotal HHH +=              (2.15) 
where Htotal  is in units of Sv.   
 
2.8 Risk prediction  
The estimated relative risk of SMN incidence in the thyroid, ERR, was estimated in two 
ways: using the traditional DMA (Equation 2.1) and the proposed DCE (Equation 2.2).  The 
model for risk of radiogenic SMN incidence in the thyroid was taken from the report of the 
BEIR VII Committee (NRC 2006).    
 
2.8.1 Risk prediction using mean absorbed dose model 
When DMA was used to estimate total absorbed dose, the estimated relative risk of SMN 
incidence, or MAERR , was calculated according to  
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where iHMA  is the total equivalent dose (Equation 15) in Sieverts in the dose-bin i when DMA is 
applied.  Vi  is the volume of the dose-bin (cc); VT is total the volume of the thyroid (cc); and 
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is the factor which describes the risk for SMNs in the thyroid per unit of equivalent dose (Sv) 
for a specific sex and age at the time of exposure.  As such, 
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where e* is defined as the age at time of exposure in years; βM is the age-specific, and organ-
specific instantaneous ERR/Sv value for males; βF is the age-specific, and organ-specific 
instantaneous ERR/Sv value for females; is the where e is the age at time of exposure in years; 
a is attained age (years); γ accounts for the per-decade increase in age at exposure over the 
range of zero to 30 years, and η represents the exponent of attained age (NRC 2006).  Thyroid 
specific values of these variables follow in Table 2 (below). 
 
Table 2.  BEIR VII committee's preferred values for modeling thyroid cancer incidence. 
Thyroid specific values of variables in the BEIR VII model are based on analyses by Ron et al. 
(1995) and a report of the NIH (2003).  Confidence intervals, CI, are shown for the age-specific 
and organ-specific values, βM and βF.  They are based on standard errors of non-sex-specific 
estimates across the studies pooled in the work by Ron et al. (NRC 2006).  
 
Variable Thyroid specific Value 
(NRC, 2006) 
Confidence Interval 
βM 0.53 (0.14, 2.0) 
βF 1.05 (0.28,3.9) 
γ -0.83 - 
η 0 - 
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 Once MAERR  was calculated, an additional term, the relative risk, RRMA, of SMN 
incidence in the thyroid was calculated using 
     1  21 3 1.     (2.19) 
Then, to determine the ratio of relative risk for incidence of SMN in the thyroid following CSI 
with proton vs. photon radiotherapies when DMA was applied, we used, 
      
protonsMA,
photonsMA,
MA RR
RR
RRR =     (2.20) 
where RRRMA is the ratio of relative risk for lifetime incidence of thyroid cancer, photons MA,RR  
and protons MA,RR  correspond to the application of equation 2.19 in the case of photon and 
proton CSI, respectively. 
2.8.2 Risk prediction using cancer equivalent dose model 
When DCE was used to estimate total dose, the corresponding value for estimated 
relative risk of SMN incidence, or CEERR  , was calculated using    
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where iHCE  is the total equivalent dose in sieverts in the i
th
 equivalent dose-bin when DCE is 
applied. The definitions for Vi , VT , and 
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  are the same as they were in the previous 
section (equation 2.16).   
Also similar to the previous section, we calculated the relative risk, RRCE, of SMN 
incidence in the thyroid using, 
     45  245 3 1    (2.22) 
and the ratio of relative risk for lifetime incidence of thyroid cancer using, 
      
protonsCE,
photonsCE,
CE RR
RR
RRR =     (2.23) 
where photons CE,RR  corresponds to the application of equation 2.22 in the case of photon and 
proton CSI.   
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2.9 Sample size calculations 
We performed three separate sample size calculations using data from our estimations 
of predicted risk, RRRMA and RRRCE, for our cohort of 18 patients.  Our first two calculations 
were used to estimate the number of patients needed for our virtual clinical trial when (1) 
RRRMA was used and (2) when RRRCE was used.  Our third calculation estimated the number of 
patients needed for a clinical trial which directly compares use of DMA vs. DCE to predict risk.   
To do this we used several freely available software programs (Dattalo 2009).  In particular, the 
two we most commonly used were a downloadable power and sample size calculator (PS 
version 3.0.43, Dupont and Plummer, 1990) and a web-based calculator (Brant 2011).  We 
used these calculators to perform (1) a two sided, one sample t-test which compared RRRMA 
against the trial’s null hypothesis, (2) a two sided, one sample t-test which compared RRRCE 
against the trial’s null hypothesis, and (3) a two sided, two sample t-test which compared, 
RRRMA vs. RRRCE.  (Details for each sample size calculation are provided in subsequent 
paragraphs.)  After we performed the sample size calculations, we inter-compared the results 
and verified them against commercial software (S-Plus version 7.0, Insightful Corp., Seattle.).  
The required input parameters for PS and the web-based calculator are summarized below in 
Table 3. 
 
Table 3. Comparisson of the input parameters used in sample size estimates for the t-test 
using two freely available statistics packages 
Input parameters slightly differed between statistics packages.  Both packages required entries 
for the experimental standard deviation of RRR, α (the probability of rejecting the null 
hypothesis when it is true), and power or (1-β) (the probability of not rejecting the null 
hypothesis when it is false).  However, PS required the difference between population means, 
d, and the web-based calculator used .  In the case of a one sample t-test using PS, d = 1- 
.  In the case of a one sample test using the web based calculator, the test population was 
compared against  = 1.  In the case of the two sample t-test using PS, d = 45.- 1.  
In the case of the web based calculator, 45 and  1 were entered.   
 
Input Parameters 
Statistics Package 
PS  
Web-based 
Calculator 
  No Yes 
Experimental Standard Deviation of 
RRR 
Yes Yes 
d  Yes No 
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α Yes Yes 
(1-β) Yes Yes 
 
 
In our final estimations of sample size, we used PS.  As a result, for the estimations 
which used the one sample t-test, we defined 'd' as the difference between our mean values of 
RRRMA and RRRCE, respectively, against the null hypothesis for our virtual clinical trial.  Our 
null hypothesis (H0) was that the ratio of relative risk for SMN in the thyroid between proton 
vs. photon radiotherapies is unity, i.e., RRR = 1.  The alternate hypothesis (Ha) was that there is 
increased predicted risk for SMNs in the thyroid when photon radiotherapy is used for CSI; 
thus the ratio of relative risk for SMN between proton vs. photon radiotherapies is less than 
one, i.e., Ha: RRR<1.  
For estimations of sample size which used the independent two sample t-test, we compared 
mean values of RRRMA and RRRCE against one another.  While this did not address the question 
posed by the virtual clinical trial, it addressed the important intermediate and related question 
of whether or not we had enough subjects in our sample group to compare RRRMA to RRRCE.  
Values of our input parameters are identical to those summarized in Table 3 with the 
distinction that 'd' compares RRRMA and RRRCE to one another instead of unity, so a 'd' value of 
zero was the null for the two sample t-test. 
2.10 Uncertainty in predicted risk 
To address specific aim two, we estimated the uncertainty associated with the mean 
RRR in the thyroid from proton CSIvs. photon CSI for one patient when RRR was determined 
using DCE and DMA, respectively.  More specifically, we first identified the predominant 
contributors to uncertainty in our estimates of RRR.  Then, we determined the sensitivity of 
RRR to these factors for one representative patient, a 10 year-old female whose age, thyroid 
size, and thyroid location approximate the corresponding mean values of our study population.   
Our estimates of relative uncertainty in RRR utilized standard error propagation 
techniques, meaning they utilized the following equation: 
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where RRRX is the ratio of relative risk defined by Equation 2.20 when X = MA and by 
Equation 2.23 when X = CE.  ERRX,protons is the excess relative risk following proton CSI as 
defined  in Equation 2.16 when X = MA and in Equation 2.21 when X = CE, and similarly, 
ERRX,photons is the excess relative risk following photon CSI for the case when X = MA or CE .  
XRRR
σ
 is the uncertainty RRRX; protonsX,ERRσ is uncertainty in ERRX  from proton CSI; and 
photons,XERR
σ
 is uncertainty in ERRX  from photon CSI.  Finally, the last term in Equation 2.24 
represents covariance.  The expanded equation for uncertainty in ERRX is determined using 
Equations 2.16 and 2.21.  Thus, 
 
2
X
2
R
22
XR








+







+





=







DwCERR
DwC
X,Q
ERRX,Q σσσσ
,    (2.25) 
where 
QX,
,
ERR
QXERR
σ
represents uncertainty in the age and gender specific risk model for SMNs in the 
thyroid from BEIR VII when the mean absorbed or cancer equivalent dose concepts are applied 
(X  =  MA or CE), respectively,  for CSI modalities (Q  =  proton or photon),
 
Cσ
 
represents 
uncertainty in the cell sterilization  factor,  
Rw
σ
 represents uncertainty in the radiation 
weighting factor for neutrons, and XDσ represents uncertainty in absorbed dose when the mean 
absorbed or cancer equivalent dose concepts are applied (X  =  MA or CE, respectively).  The 
methods for determining specific values of Cσ , Rwσ , and XDσ are outlined in the following 
sections. 
2.10.1 Uncertainty in absorbed dose, XDσ  
In this section we present our methodology for estimating uncertainty in absorbed dose 
in the thyroid due to variations in patient-set up for proton vs. photon CSI.  Recall that our 
estimates for risk of SMNs in the thyroid are determined based on voxelized regions of dose, 
consequently, small inter-fractional shifts in the location of the thyroid relative to the radiation 
field can potentially impact estimates of DMA and DCE.  The location of the thyroid for our 
representative patient is shown in Figure 9. 
24 
 
 
 
 
Figure 9. Thyroid location with respect to treatment field in representative patient 
Sagittal images were taken of the left lobe of the thyroid for a 10 year-old female patient 
(patient #14) with a prescribed dose of 2340 cGy (RBE) from proton (a) and photon (b) CSI.  
The thyroid, outlined in pink, is located well away from the junction of the cranial and upper 
spine field junction (yellow box). (a) Field edges and dose (cGy RBE, RBE factor of 1.1)) are 
shown for proton CSI.  (b) Field edges and dose (cGy, RBE factor of 1.0) are shown for photon 
CSI.  (c) Dose scale for (a) and (b).  
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To estimate uncertainty in absorbed dose, we estimated the effect of inter-fraction 
shifts, between the therapeutic treatment field and the thyroid, on therapeutic dose in the 
thyroid.  Briefly, we calculated the differences in therapeutic dose in the thyroid after 
representative shifts (in the anterior, posterior, superior, inferior, and lateral directions).  Then 
we used the largest interval in dose to represent uncertainty in absorbed dose.  The magnitude 
of the inter-fraction shifts was selected using clinically determined values for uncertainty in 
patient set-up (Table 4).   These values represent the prevailing SOC for proton and photon 
CSI, respectively, at our institution, at the time of this study. 
 
Table 4. Values for set-up uncertainty per prevailing standards of care for proton and 
photon CSI. 
Selected set-up uncertainties used in proton and photon CSI.  In the bottom row, are the values 
we used for our uncertainty analysis.  They correspond to the uncertainty associated with the 
spinal fields when the practice of daily imaging is followed (per the SOC for pediatric CSI).   
 
Values for set-up uncertainty Proton CSI                                                         (cm) 
Photon CSI                  
(cm) 
Face mask and head holder  0.3 0.3 
Alpha cradle or Med-Tec device 0.5 0.5 
Index to treatment couch 0.7 0.7 
Daily imaging + index to treatment couch 0.5 0.5 
Values selected for uncertainty analysis                                           
(spinal field) 0.5 0.5 
 
Table 4 includes uncertainties for the brain and spine fields and varies according to 
immobilization type.  In our sample, immobilization for brain fields included use of a 
thermoplastic face mask and head holder.  For spine fields immobilization included indexing to 
the treatment couch (on a Styrofoam pad).  Additionally, per the current SOC for pediatric 
patients, daily imaging was included in the patient set-up.  We selected an uncertainty value of 
0.5 cm.  This value is conservative because it is based on the larger uncertainty associated with 
the spinal field rather than the smaller uncertainty of the cranial fields.  
We used the value of 0.5 cm for set-up uncertainty in proton and photon CSI to 
simulate possible variations in the position of the thyroid relative to the planned treatment 
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fields.  This was done for one representative proton treatment plan and one representative 
photon treatment plan for the same patient.  Simulation of thyroid motion relative to its 
respective treatment fields was achieved by shifting its contour within the treatment planning 
system by the maximum set-up uncertainty value in the superior, inferior, left, right, anterior, 
and posterior directions.  The mean absorbed dose was recorded for each contour location, and 
the maximum difference in absorbed dose was used to estimate the associated uncertainty in 
absorbed dose associated with variations in thyroid location due to patient set-up for proton and 
photon CSI.    
 
2.10.2 Uncertainty in the cell sterilization factor, Cσ  
In this section we present our methodology for determining the sensitivity of our risk 
predictions to uncertainty in the cell sterilization factor, C (Equation 2.3), for proton vs. photon 
CSI.  Uncertainty in C is due to the uncertainty of a thyroid specific factor alpha, α, which was 
defined following the methods of Schneider et al. (2005).  Estimates for α were reported using 
data from Hodgkin’s patients (Schneider et al. 2005).  However, there has been some debate 
over the applicability of data from Hodgkin’s patients to all patient populations (Kry and 
Salehpour 2006).  In particular, there is concern that Hodgkin’s patients may be more 
susceptible to thyroid cancer than the general population due to genetic or environmental risk 
factors (Ronckers et al. 2006).  Yet, there are epidemiological results which suggest that cell-
sterilization occurs in the thyroid similarly for non-Hodgkin’s patients as well as Hodgkin’s 
patients (Sigurdson et al. 2005).   As a result, there is a numerically unknown, yet inherent, 
uncertainty associated with α.  To address this in our work, we estimated the sensitivity of our 
estimates of risk to an interval of α values which were defined using the following (Schneider 
et al. 2005): 
}047.0020.0:CI|033.0{)Sv( 1 −=−α .  (2.26) 
where the minimum value is 0.020 Gy-1 or αMIN , the nominal value of α is 0.033 Gy-1 or α*, 
and the maximum value was 0.047Gy-1 or αMAX.  Then, we applied the interval of α values to 
the following to determine the corresponding cell sterilization factor, @ for proton and photon 
CSI using (adapted from Equation 2.3), 
@A  BCDEFGHIJ , (2.27) 
where the subscript ‘x’ indicates MIN, nominal, or MAX and  79  is defined from Equations 
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2.12b and 2.15.   Next, we used the interval between @KL and  @1M  to conservatively estimate 
the sensitivity of our risk estimates to uncertainty in α using,
 
 . C MINMAXC −≈Cσ     (2.29) 
where Cσ  represents  uncertainty in the cell sterilization  factor.  After that, we divided by the 
nominal correction factor, C.  
 
2.10.3 Uncertainty in the neutron weighting factor, 
Rw
σ
 
This section describes the method used to estimate the uncertainty in the mean radiation 
weighting factor for neutrons, 
Rw
σ .
 
In this project we used values of Rw  that were published 
by Newhauser et al. (2009), but to maintain the validity of our study results we also determined 
the sensitivity or our results to uncertainty in Rw .  To do this, we used the results of previous 
works by Yan et al. (2002) and Newhauser et al. (2009) to determine the most representative 
values for scaling Rw .  More precisely, we scaled Rw by 0.5 and 2 to represent a bracket of 
uncertainty in Rw .   Once we scaled our values of Rw , we applied these values to our 
estimates for stray neutron dose.  This created an interval of values of Htotal (Equation 2.15) 
which resulted in a corresponding interval of values of RRRX where X = MA or CE.  We then 
used the resulting intervals for RRRX  to define an uncertainty factor for Rw in proton CSI as 
follows: 
NOP,Q  |Q!  0.5# ) Q!  2#|,       (2.30) 
where NOP,Q
 
represents uncertainty in the neutron weighting factor when RRR is determined 
using DMA  or DCE, i.e., X = MA or CE.  Finally, because we wanted a general estimate for 
uncertainty in the field-averaged Rw , as opposed to a field-specific estimate, we divided by 
the mean value for Rw  across all treatment fields (last entry in Table 5 below) to satisfy the 
term for the neutron weighting factor,
R
R
w
w
σ
, from Equation 2.25.  This was done for one patient 
receiving proton CSI; the same patient identified in section 2.9.1 above.  As a result, there was 
no mid spine field.  A similar test was not performed for photon CSI because neutrons are not 
produced for 6 MV photon beams. 
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Table 5.  Radiation weighting factors for neutrons for uncertainty test patient 
Neutron weighting factors which were used in the case of our representative patient are listed.  The 
mid spine field was not required for full coverage of the spinal axis.  Also listed is the mean of 
the field-specific values of Rw .  
 
 
Field T value 
Cranial (LPO) 7.75 
Cranial (RPO) 7.75 
Upper Spine 8.09 
Mid Spine - 
Lower Spine 8.13 
Mean 7.93 
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Chapter Three 
 
3 Results  
This chapter presents the results of this study.   Ultimately, it details our findings for the 
effect of cell sterilization on sample size in a study of the predicted risk of a SC in the thyroid 
following pediatric CSI with proton vs. photon therapy.  To do this, we first estimated the 
effects of DMA vs. DCE on therapeutic dose (3.1), stray dose (3.2), the combination of 
therapeutic and stray dose in terms of total equivalent dose (3.3), and the predicted risk of SC 
incidence in the thyroid (3.4).   Then, using our values of predicted risk, we determined the 
corresponding sample size needed for statistical significance (3.5).  In addition, this chapter 
provides the results of our uncertainty analysis of predicted risk (3.6).   
 
3.1 Estimation of therapeutic dose 
3.1.1 Therapeutic dose  
We used dDVH information and a spreadsheet to estimate values of DMA (equation 2.5) 
and DCE (equation 2.6) using the therapeutic dose (Gy) in each patient’s thyroid (Table 6).  
Stray dose (Sv) (section 3.2) was added in section 3.3 to form equivalent dose (Sv). 
 
Table 6.  DMA and DCE from our spreadsheet for proton and photon CSI    
Estimates of DMA and DCE from our spreadsheet are shown.  The estimates were made using 
therapeutic dose in the thyroid. 
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The distribution of values for DMA and DCE in Table 6 is shown in Figure 10. 
 
Figure 10.  Distribution of DMA for proton and proton CSI 
 (a) DMA and DCE in the thyroid for therapeutic dose from proton CSI (b) DMA and DCE in the 
thyroid for therapeutic dose from proton CSI on a semi logarithmic plot (c) DMA and DCE in the 
thyroid for photon CSI. 
To cross check our spreadsheet (Table 6), we compared the distribution of DMA values 
in the spreadsheet against the corresponding DMA values calculated by the TPS.  The results of 
the comparison are presented in Tables 7 and 8 below. 
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Table 7. DMA from TPS vs. DMA from our spreadsheet for photon CSI. 
Descriptive statistics for the distribution of DMA in the thyroid from photon CSI for our sample 
of 18 patients are provided.    Data which correspond to TPS estimations of DMA are found in 
column A.  Data which correspond to spreadsheet estimations of DMA are found in column B.  
Column C lists the absolute value of the difference between data in columns A and B.  Column 
D lists the percent difference between values from columns A and B. Negative values in 
columns C and D indicate that spreadsheet estimates of DMA are larger than those from the 
TPS.  Conversely, positive values in columns C and D indicate that TPS estimates of DMA are 
larger than those from the spreadsheet. 
 
 
 
From Table 7 for photon CSI, we saw that for our sample of 18 patients, the percent difference 
between mean values of  DMA from the TPS vs. spreadsheet was less than 1%.  Similarly, there 
was less than 1% percent difference in the experimental standard deviation and the standard 
deviation of the experimental mean of DMA when the TPS vs. spreadsheet was used.  
Additionally, when the maximum estimate of DMA, DMA, MAX, from the TPS was compared to 
DMA, MAX  from the spreadsheet, the spreadsheet estimate was 2% higher.  Conversely, when 
the minimum estimate of  DMA, DMA, MIN, from the TPS was compared to DMA, MIN from the 
spreadsheet, the spreadsheet estimate was 2% lower.   The interval between DMA, MAX and DMA, 
MIN was almost 5% higher for the spreadsheet vs. TPS estimates.  Thus, while there were 
differences in rounding and truncation between the spreadsheet and TPS, estimates for DMA 
they were considered acceptable. 
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Table 8. DMA from TPS vs. DMA from our spreadsheet for proton CSI. 
Descriptive statistics for the distribution of DMA in the thyroid from proton CSI for our sample 
of 18 patients are provided.    Data which correspond to TPS estimations of DMA are found in 
column A.  Data which correspond to spreadsheet estimations of DMA are found in column B.  
Column C lists the absolute value of the difference between data in columns A and B.  Column 
D lists the percent difference between values from columns A and B.  Negative values in 
columns C and D indicate that spreadsheet estimations of DMA are larger than those from the 
TPS. 
 
 
In Table 8, we found that the population averaged DMA from proton CSI was 
approximately 400 times smaller than those for photon CSI (Table 7).   Also, in Table 8 we 
found that for proton CSI, the percent difference between mean values of DMA from the TPS 
vs. spreadsheet was less than 2% with the spreadsheet values being larger.  Similar to photon 
CSI, there was less than 1% percent difference in the experimental standard deviation and the 
standard deviation of the experimental mean of DMA when the TPS vs. spreadsheet was used.  
Additionally, when the maximum estimate of DMA, DMA, MAX, from the TPS was compared to 
DMA, MAX  from the spreadsheet, the spreadsheet estimate was almost 1% higher.   However, 
when DMA, MIN from the TPS was compared to DMA, MIN from the spreadsheet, the spreadsheet 
estimate was 34% lower.   To understand the reason for this difference, we reviewed the 
original TPS and spreadsheet distributions of DMA for proton CSI (distributions values not 
shown here).  From the distributions we found that while there the mean difference in estimates 
for DMA from the TPS vs. spreadsheet is small, -0.08 cGy (RBE), there are specific instances 
where differences as low as -0.04 cGy (RBE) can result in  a 44% percent difference.   
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To determine the potential impact of these small differences on our estimates of thyroid 
dose for proton patients, we classified patients with a percent difference greater than 10% as 
outliers.  Three of 18 patients were qualified as outliers.   We compared their DMA values as 
well as any physical attributes such as the size and anatomical location of the thyroid, gender, 
or age that could potentially explain the differnces in DMA.  Data for these patients is 
summarized in Table 9 and Figures 11 and 12 below. 
 
Table 9. Outliers from the comparison of DMA estimates from the TPS vs. spreadsheet for 
proton CSI   
Values of therapeutic mean absorbed dose from proton CSI are compared for three patients.    
Column A lists values determined by the treatment planning system (TPS), and column B lists 
values that were determined by taking the volume weighted average of dose values in our 
spreadsheet.  Column C lists the difference between columns A and B, and column D reports 
the percent difference between columns A and B.  Additional physical characteristics are listed 
in columns E-I.  For comparison mean values for the entire sample (N = 18) are listed in the 
last row. 
 
 
  
 From Table 9, we found two main trends.  (1) The three outliers have comparatively 
small DMA values when compared to the mean DMA values of 5.0 cGy (RBE) for the entire 
sample (Table 8).  (2) The three outliers have comparatively large thyroid volumes (≥ 10 cc) 
when compared to the mean thyroid volume of 5.8 cc for the entire sample.  We stratified our 
sample by the size and relative anatomical location of the thyroid and patient sex (Figures 11 
and 12 below).   
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Figure 11. Sex-specific histograms: size and relative anatomical location of the thyroid  
 (a) Frequency distribution of thyroid volume. (b) Frequency distribution of distance along the 
treatment axis from the surface of the patient’s skin to the center of the patient’s thyroid. (c) 
Frequency distribution of physical distance along the treatment axis from the surface of the 
patient’s skin to the anterior-most point of the patient’s thyroid. 
 
 Figure 11 reveals that there are potential sex-related trends in our sample.  For example, 
in Figure 11a, the inter-patient variation in thyroid volume was smaller for females than males.  
In the male patients, thyroid volume was fairly evenly distributed from 3 to 15 cc.  Figures 11b 
and 11c which plot the inter-patient variation in the location of the thyroid show that the 
variation was also smaller for females than males.  To further investigate these trends, we 
plotted our values of thyroid volume and depth within the patient with respect to the patient age 
at exposure (Figure 12). 
35 
 
 
Figure 12.  Sex-specific thyroid volume and physical depth from skin vs. patient age at 
exposure 
 (a) Distance along the treatment axis from the surface of the patient’s skin to the center and 
anterior-most surface of the thyroid vs. patient age at exposure (e).  Patient information is 
stratified according to sex.  (b) Thyroid volume (V) vs. patient age at exposure (e).  
 
Figure 12 indicates that there may be correlations with respect to sex and thyroid location.  
Thyroid depth and volume increased with respect to age at exposure for both sexes, and this 
increase was more pronounced for males than females.   
Using the data in Figures 11 and 12, we performed one final analysis.  We created a 
scatter plot to test for a statistically significant correlation between thyroid volume (cc) and the 
difference between DMA values from the TPS and our spreadsheet (Figure 13). 
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Figure 13. Percent difference in DMA between TPS and spread sheet estimates 
Thyroid volume (V) vs. percent difference between the TPS and spreadsheet based estimates of 
mean absorbed dose.  A trend line and coefficient of determination (R2) are also shown, and 
from R2, the correlation coefficient (R) is 0.61. 
 
From Figure 13, we see that a strong positive correlation between differences in DMA and 
thyroid volume was not observed.   While visual inspection may suggest that a thyroid volume 
that is larger than 10 cc may correspond to a larger percent difference between the TPS and 
spreadsheet estimates for mean absorbed dose, there is too much variation within our data to 
make a conclusive statement.  Essentially, a larger sample size is needed to conclusively 
explain the difference between the TPS vs. spreadsheet estimates for DMA in terms of partial 
volume effects, age at exposure, and sex.   However, because the number of outliers, 3, was 
relatively small when compared to our overall sample size of 18 patients, we elected to 
continue use of the spreadsheet to estimate values of DMA and, in turn, DCE.   
 
3.2 Estimation of stray dose 
The results of our MC simulations for stray dose to the thyroid are summarized in Figure 
14 and Table 10 below. 
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Figure 14.  Stray dose from proton CSI 
Calculated stray dose to the thyroid vs. age  at exposure (e).    
 
From Figure 14, we see that for 17 of the 18 patients, the majority of Hstray are between 400 
mSv and 500 mSv.  One patient, patient index 1, had Hstray closer to 700 mSv.  Patient #1 was a 
13 year-old female patient whose therapeutic dose from proton CSI was 17.6 times that of the 
mean therapeutic dose for our sample (Tables 6 and 7, Figure 10).  To determine the impact of 
this patient’s therapeutic dose on the estimation of stray dose for our sample, we reported 
summary statistics for several sub-groups within our sample: a group which includes patient 1, 
a group which excludes patient 1, all males, and all females (Table 10). 
 
Table 10.  Stray dose from proton CSI 
Summary statistics for patients shown in Figure 14.  Column A lists summary statistics for all 
patients shown (N = 18).  Column B lists summary statistics for all patients except patient #1 
(N = 17).  Column C lists summary statistics for all males (N = 10).  Column D list summary 
statistics for all females, including patient #1 (N = 8).  
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  From Table 10 above, the mean DMA for the sample was 437 mSv, but when DMA for 
patient 1 was removed from the sample, the mean DMA decreased by 4% to 423 mSv. This 
suggests the importance and impact of patient-specific variations on descriptive statistics of a 
small sample group.  Additionally, the maximum values for mean dose dropped by 20% (i.e., 
from 683 mSv to 547 mSv) when the high dose patient was removed.  However, we also saw 
that, the mean value of stray dose was slightly higher for males, 1.6%, than females, even when 
the female population contained an identified high dose patient.   
 
3.3 Estimation of total equivalent dose  
Table 11 lists the total equivalent dose, Htotal, from proton CSI; it is the combined 
contribution of stray and therapeutic radiation in the thyroid.  Htotal values were calculated 
using  DMA and DCE.   
Table 11. Total equivalent dose proton CSI 
Values are shown for Htotal, when DCE  vs. DMA is applied, resulting in predicted values of HCE 
and HMA, respectively.  HCE and HMA are listed for 18 patients in columns A and B.  Columns 
C and D compare the results in columns A and B via absolute difference and percent absolute 
difference. 
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Figure 15 (below) plots the values of total equivalent dose, Htotal, listed in Table 11. 
 
Figure 15. Total equivalent dose proton CSI 
Total equivalent dose, Htotal, verses age at exposure (e). Htotal values were calculated using  DMA 
and DCE.  They are plotted as HMA and HCE.   
 
Table 12.  Total equivalent dose proton CSI: summary statistics 
Summary statistics are listed for our sample of 18 patients.  Columns A and B present results 
for the total equivalent dose when DMA and DCE were used, respectively.  Columns C and D 
compare the results in columns A and B via absolute difference and percent absolute 
difference. 
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In Figure 15, we saw no evidence of a relationship between Htotal and e.  Also, in Table 
12, we see that for proton CSI, the mean difference between values of HMA vs. HCE was only 
2%.  However, there is an 11% larger experimental standard deviation and an 8% higher 
maximum value for HMA vs. HCE.  This supports the patient specific results (Table 11) which 
suggested that there were specific instances where use of DCE did make a difference.  For 
example, for patients 1 and 11 there was a 91 mSv and 18 mSv decrease in dose, and for 
patients 9 and 5 there was a 10 mSv decrease (Table 11).  Additionally, while patients 1, 11, 9, 
and 5 had the four largest HMA and the four largest differences between HMA and HCE, the 
difference between HMA and HCE did not directly scale with dose.   Patient 9 and patient 5 each 
had a 10 mSv decrease from HMA to HCE, but their HMA was 560 mSv and 527 mSv, 
respectfully.  In the case of patient with the largest HMA, patient 1, HMA was 1143 mSv, and 
HCE was 1051 mSv, thus the difference between HMA and HCE for the high dose patient was 91 
mSv.  This is 8 times larger than the mean difference for the sample, i.e., 12 mSv.  Thus, use of 
DCE normalized the effect of small differences in dose on Htotal. 
In Figure 16, we switch the focus from proton CSI to photon CSI.   Similar to Figure 15 
for proton CSI, values of total equivalent dose are presented in graphical and tabular form.  In 
both cases, we compare values of Htotal when DMA vs. DCE are applied to our sample population, 
i.e., we compare HMA vs. HCE. 
 
 
Figure 16. Total equivalent dose photon CSI  
Total equivalent dose, Htotal, is plotted against age at exposure (e). 
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Table 13. Total equivalent dose photon CSI 
Values are shown for Htotal, when DCE  vs. DMA is applied, resulting in predicted values of HCE 
and HMA, respectively.  Estimations for HCE and HMA are provided for 18 patients in columns A 
and B.  Columns C and D compare the results in columns A and B via absolute difference and 
percent absolute difference. 
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Table 14.  Total equivalent dose photon CSI: summary statistics 
Summary statistics are shown for our sample of 18 patients.  Similar to Figure 15, columns A 
and B present results for the total equivalent dose when the mean absorbed and cancer 
equivalent dose concepts are applied, respectively.  Columns C and D compare the results in 
columns A and B via absolute difference and percent absolute difference. 
 
 
 
 From Figure 16, we see that values of Htotal decrease dramatically when DCE is applied, 
and that the interval in Htotal when  DCE vs. DMA are used increases with age at exposure.   Table 
14 reveals that the difference between mean values of Htotal  is 6,6264 mSV with  photon CSI 
vs. 12 mSV with  proton CSI.  Additionally, with photon CSI, the percent difference in the 
interval of Htotal when  DCE vs. DMA are used is  62% vs.  11% for proton CSI (Table 12).   On 
the other hand, the experimental standard deviation of HMA vs. HCE is smaller for photon CSI 
vs. proton CSI, i.e., 23.3% and 15.6%, respectively, for proton CSI vs. 36.1% and 32.9%, 
respectively, for photon CSI.  Thus, there was less variation in the mean values of HMA and HCE 
for photon CSI than for proton CSI (Tables 12 and 14). 
 To determine if there were additional trends in the difference between HMA and HCE for 
photon CSI, we plotted the absolute difference in HMA vs. HCE with respect to age at exposure 
(Figure 17).   
 
Figure 17. Absolute difference between 
The absolute difference between 
patients. 
 
Figure 17, reveals that | HMA 
exposure.  However, we would need more data
old to make a definitive statement
be a significant sex-specific difference in |
To further characterize the contribution of stray dose within our study, we compared the 
values of stray dose to therapeutic dose (Table 15 below) in the cases of proton and photon 
CSI. 
 
Table 15. Comparison of therapeutic doses to stray dose
Summary statistics for our sample of 18 patients are 
populated in the case of photon CSI because the thyroid was in the exit region of the field.  
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 From Table 15, we found that for proton CSI, the mean Htherapeutic was 50 mSv while the 
mean Hstray was 437 mSv.  As a result, the mean Htherapeutic was 11% of the mean Hstray.  
Correspondingly, the minimum Htherapeutic was less than 1% of the minimum Hstray , and the 
maximum value of Htherapeutic was 67% that of the maximum value for stray dose.  Thus for 
proton CSI, the importance of including stray radiation is underscored. To further understand 
the difference between HMA and HCE for photon vs. proton CSI, we focused on their 
fundamental main difference, the cell sterilization factor, C, (Equation 2.3).   Because C was 
estimated on a voxel by voxel basis, we determined the mean cell sterilization factor for each 
patient’s thyroid, @U, and plotted those values against age at exposure, e, for proton and photon 
CSI (Figure 18). 
 
Figure 18.  Cell sterilization factor for proton and photon CSI. 
Mean cell sterilization factor, @U, was plotted against age at exposure for proton and photon 
CSI.  The population averaged @U for proton CSI was 0.95.   The overall mean @U for photon CSI 
was 0.72.  The dashed line indicates a correction factor of 1.0. 
In Figure 18, we see the same underlying patterns as we did in Figures 15a and 16a.  
For the case of proton CSI, Figure 18 shows that @U was approximately 1 for all patients except 
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patient 1, the patient who received the highest dose to the thyroid.  For the case of photon CSI, 
@U for the high dose patient was 0.78 which is closer to the mean @U for photons, 0.72.  
3.4 Risk prediction  
In this section, we present results of estimates of the risk of second cancers in the 
thyroid.  To do this we applied the model for risk of SMNs in the thyroid from the report of the 
BEIR VII Committee (NRC 2006).  The model was applied to HMA and HCE.  
3.4.1 Relative risk estimates from photon vs. proton CSI  
 Figure 19 plots the distribution of values of the predicted relative risk, RRMA and RRCE, 
of second cancers in the thyroid after photon vs. photon CSI (Equations 2.19 and 2.22). 
 
Figure 19.  Relative Risk estimates for photon and proton CSI vs. age at exposure 
The relative risk, RR, of second cancers in the thyroid from photon CSI and proton CSI is plotted 
on a logarithmic scale against age at exposure, e.   RRMA is the estimate of RR when DMA was 
used to estimate total equivalent dose, and RRCE is the estimate of RR when DCE was used to 
estimate total equivalent dose. 
 
 Figure 19 indicates that after photon and proton CSI, RR values decrease with age at 
exposure.  Also, similar to the graphs of Htotal and C, we see that, in general, our results for 
photon CSI are more sensitive to use of DMA vs. DCE than our results for proton CSI.   To 
elucidate the differences in RR for photon vs. proton CSI, we plotted the results from Figure 18 
on a semi-log scale (Figure 20). 
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Figure 20.  VV  estimates for photon and proton CSI vs. age at exposure 
The   from photon CSI and proton CSI are overlaid on the plot from figure 19. 
 
  Figure 20 shows that  for photon CSI is larger than  for proton CSI by factors of 
12 and 20 when DMA and DCE are applied, respectively.  Additionally, Figure 19 demonstrates 
that use of DCE  reduces  by almost 60% for photon CSI and has negligible effect for proton 
CSI (high dose patient, patient 1, included).   To further analyze our results for RRMA and RRCE, 
we plotted the difference between RRMA and RRCE against patient age in years (Figure 21a) and 
the ratio of RRCE to RRMA against patient age at exposure (Figure 21b).   
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Figure 21. Comparison of RRMA to RRCE 
In (a) the difference between estimates for RR for each patient (N = 18) when DMA and DCE are 
applied is plotted against patient age at exposure in years, e, for proton and photon CSI.  In (b) 
the ratio of estimates for RR for each patient (N = 18) when DMA and DCE are applied is plotted 
against patient age in years, e, for proton and photon CSI, i.e., the ratio of RRCE to RRMA is 
plotted against ‘e’ for proton and photon CSI. 
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Figure 21 reveals that the relationship between RRMA and RRCE is fairly constant with 
respect to age at exposure.  There is a slight increase in the difference between RRMA and RRCE 
(Figure 21a) for patients that are less than 5 years old.  However, there are not enough data 
points in that region to provide conclusive results. 
3.4.1.1 Sex specific trends for relative risk estimates 
When the risk model (Equation 2.16 or 2.21) is applied to our estimates of HMA or HCE, 
there is an inherent difference in how it is applied to male vs. female patients.  In particular the 
values of the age-specific and organ-specific values, βM and βF, differ for males and females, 
respectively (Table 2).  The ratio of βM  to βF  is 0.5.  As a result, we expected that regardless of 
the radiation source, proton CSI or photon CSI, we would see a ratio of RR in males to RR in 
females of approximately 0.5.  Our results from this comparison are listed in Table 16 below. 
 
Table 16.  Ratios of male-to-female values of dose, risk, and risk coefficient 
The ratio of mean values in male vs. female patients for: 	Wtherapeutic, Wstray, Wtotal,  using DMA, 
  using DCE, and the age-specific and organ-specific risk models from BEIR VII are listed 
for proton CSI and photon CSI.  Data for the female patient receiving the highest dose from 
proton CSI was excluded from this analysis. 
 
  
The data in table 16 reveals that for our sample, female patients received almost twice 
the therapeutic dose from proton CSI to the thyroid as males and 10% more stray dose.  
Because the contribution from stray dose dominated total equivalent dose in the case of proton 
therapy (Table 15), the combined effect of therapeutic and stray dose resulted in only 10% 
more total equivalent dose from proton CSI for females than males.   
A similar result was found for photon CSI.  Correspondingly, the ratio of male to 
female values of RR was 0.7 to 0.8, or approximately 60% higher than expected from βM / βF.  
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While these results seem to support the analysis in section 3.1.1, due to our limited sample 
sizes (8 females, 10 males), they did not reveal a significant relationship between sex and dose 
or predicted risk of second cancers in the thyroid. 
  
3.4.2 Ratio of relative risk estimates for photon vs. proton CSI  
 In this section we compare the RR from photon and proton CSI by taking their ratio.  
We termed this the ratio of relative risk or RRR.  Because this was done for RR values which 
were estimated using DMA and DCE (Equations 2.20 and 2.23), our corresponding terminology 
for RRR was RRRMA and RRRCE, respectively. 
 
 
Figure 22. Ratio of relative risk after proton vs. proton CSI 
Predicted ratio of relative risk (RRR) between proton vs. proton CSI are plotted against age at 
exposure, e.   The first estimation (open triangles) utilizes DCE (RRRCE), and the second (closed 
triangle) utilizes DMA (RRRMA). 
 
 Figure 22 indicates that RRR is typically higher when DCE (RRRCE) is applied vs. when 
DMA (RRRMA) is applied.  This finding restates our previous results that RRCE was consistently 
lower than RRMA in the case of photon CSI and approximately equal in the case of photon CSI 
(Figure 20).  More specifically, from Figure 20, we saw that for photon CSI the mean value for 
RRCE was 60% lower than the mean value for RRMA, and for proton CSI there was a negligible 
difference.   The impact of these differences on the predicted RRR is shown in Table 17 for our 
patient sample.   
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Table 17. Ratio of relative risk from photon vs. proton CSI when DCE  vs. DMA is applied 
Values are shown for RRR when DCE  vs. DMA is applied, resulting in predicted values of 
RRRCE and RRRMA, respectively.  Estimates of RRRCE and RRRMA are provided for 18 patients 
in columns A and B.  Columns C and D compare the results in columns A and B via absolute 
difference and percent absolute difference. 
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Table 18.  Summary statistics for the ratio of relative risk after photon vs. proton CSI 
Summary statistics for Table 17 are provided.  Columns A and B present results for the ratio of 
relative risk (RRR) from photon vs. proton CSI when the mean absorbed and cancer equivalent 
dose concepts are applied, respectively.  Columns C and D compare the results in columns A 
and B via absolute difference and percent absolute difference.  
 
 
 
From Tables 17 and 18, the mean value of RRR increased by 67% when it was 
estimated using DCE vs. DMA.   The percent differences between maximum values and 
minimum values of RRR are 62% and 74%, respectively for RRRCE vs. RRRMA.  This reflects 
the sensitivity of the RRR to patient specific variation. Visual representation of the data for 
columns A and B is found in Figures 23 and 24 below.    
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Figure 23. Differences in estimates for RRR when DMA vs. DCE were used 
The difference in estimates for RRR when the DCE  vs. DMA concept is applied, i.e., RRRCE and 
RRRMA, respectively, is stratified by sex and plotted against patient age, e.  
 
 
Figure 24. Percent difference in estimates for RRR when DMA vs. DCE were used 
The percent difference in estimates for RRR when DCE  vs. DMA is applied, i.e., RRRCE and 
RRRMA, respectively, is stratified for sex and plotted against patient age, e. 
 
In a final analysis of our estimates for RRRCE and RRRMA we performed three t-tests 
using S-Plus.  These tests were performed to determine if our estimates for RRRCE vs. RRRMA 
were statistically different from the null hypothesis (RRR = 1) and one other.    In our first test, 
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we compared the mean value of RRRMA against RRR = 1 .  In the second test, we compared the 
mean value of RRRCE against RRR = 1, and in the third test, we used a paired t-test to compare 
the mean value for RRRCE against the mean value for RRRMA (Table 19).  
 
Table 19. Results of t-test to determine if there is a statistically significant difference 
between RRRCE vs. RRRMA 
Column A shows results of a t-test for one sample in which the mean value for RRRMA is 
compared to RRR = 1.  Column B shows results of a t-test for one sample in which the mean 
value for RRRCE is compared to RRR = 1.  Column C shows results of a paired t-test for two 
sample means: RRRCE and RRRMA.  All tests were performed for our patient sample (N = 18).  
The results for the two-tail test are highlighted in yellow because they are most relevant to the 
virtual clinical trial in this work. 
 
 
 
 Table 19 provides results for a one-tail and two-tailed t-test.  For either test and in all 
columns, the reported p-values are much less than 0.05, thus there is very strong statistical 
evidence that both RRRMA and RRRCE are significantly different from unity.  Similarly, there is 
very strong evidence of statistically significant difference between RRRCE and RRRMA.   
 
3.4.2.1 Sex specific trends for the ratio of relative risk for photon vs. proton CSI 
Our estimates for RRRCE and RRRMA show no identifiable trend with respect to sex.  
Additionally, comparisons of RRRCE and RRRMA (Figures 23 and 24) also show now difference 
with respect to sex.  This is an expected result because according to Equations 2.20 and 2.22, 
the sex specific terms in the risk model, βM and βF, cancel when the ratio of RR values is taken. 
 
3.5 Sample size estimations  
We performed three separate analyses of sample size.   Our first two analyses were the 
most relevant to our virtual clinical trial because they estimated the number of patients needed 
to determine a statistically significant difference in predicted risk from proton vs. photon CSI 
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for two cases: (1) the case when DMA was used to determine predicted risk and (2) the case 
when DCE was used to determine predicted risk.  Our third analysis addressed the related 
question of whether or not we had enough subjects to compare estimates for predicted risk 
using DMA vs. DCE.   
In our first analysis we considered the case in which a patient population was 
characterized using the mean value and experimental standard deviation of RRRCE as 
determined in our work.  In our second analysis we considered the case in which a patient 
population was characterized using the mean value and experimental standard deviation of 
RRRMA as determined in our work.  In these first two analyses we used the one sample t-test in 
which we compared our mean values of RRRMA and RRRCE, respectively, against the null 
hypothesis for our virtual clinical trial, i.e., H0: RRR = 1. 
Table 20. Sample size estimation for one sample t-test 
Results are shown for three sample size estimators, two freely available statistical packages and 
S-Plus.  Input into the estimators included mean RRR for our patient population (N = 18), the 
experimental standard deviation (σRRR) for our patient population (N = 18), and the desired 
values of α and power (1-β) which were 5% and 80%, respectively.  Output from the 
estimators was given as the minimum sample size needed to achieve 5% for alpha and 80% 
power.  Differences in estimates for the required sample size between software packages are 
most likely the result of differences in the software’s rounding, i.e., a sample size of 0 vs. 1, 
and truncation of reported results.   
 
 
The results for our sample size estimates in Table 20 indicate that the sample size 
required for 80% power is at most 1, regardless of whether DCE or DMA was applied.  One 
reason for this finding is that our estimates for RRRMA and RRRCE are 20 to 12.5 times lower 
than that of our null hypothesis (RRR = 1).  Additionally the variation or experimental standard 
deviation of our sample was very small.  As a result, the estimators calculated that at most one 
patient was needed to show that the risk of second cancers in the thyroid is reduced with proton 
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CSI vs. photon CSI.  Thus, according to our estimation for sample size, use of DCE to reduce 
sample size becomes an un-necessary step.   
In our second analysis of sample size, we estimated the number of patients needed if 
one were to perform a study which directly compared predicted risk using DMA vs. DCE.   To do 
this we used a two sample t-test in which we compared our mean values of RRRMA to our mean 
values of RRRCE.  More precisely, we were no longer comparing our estimates for RRR against 
the null hypothesis: we were instead comparing RRRMA to RRRCE.  Thus, in this estimation, the 
estimates for sample sizes represent the number of patients needed to see a significant 
difference between RRRMA and RRRCE (Table 21).   
   
Table 21. Sample size estimation for two sample t-test 
Results are shown for two sample size estimators (freely available statistical packages).  
Sample size was estimated for two data sets.  In the first data set we included all patients in the 
study (N = 18),   In the second data set, we excluded the patient receiving a notably high dose 
from proton CSI, patient #1, (N = 17).  Input for each data set included values of mean RRR, 
the experimental standard deviation ( σRRR ), and our desired values of (α )and power (1-β)  
which were 5% and 80%, respectively.  Output from the estimators was given as the minimum 
sample size needed to achieve 5% for alpha and 80% power. 
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In Table 21, estimates of required sample size increased relative to the estimates for the 
one sample t-test (Table 20).  One reason for the increase is that when we switched to a two 
sample t-test, statistical variation within each sample was increased.  This occurred because 
each sample no longer served as its own control.  However, even with the increase in required 
sample size, Table 21 revealed that our sample size (N = 18 ) is large enough to demonstrate 
that RRRMA and RRRCE were statistically different from each other when the t-test is used.  
Thus, in future studies, it is reasonable to expect that two samples, in which the predicted RRR 
is determined using different methods, can be directly compared. 
To generalize the trends from Tables 18 (RRR) and 20 (corresponding sample size), we 
performed a more broadly-applicable analysis.   That is, we used the input parameters in Table 
18 (restated in Table 22 below) and the PS software (Dupont and Plummer 1990) to generate 
curves for sample size for 1 and 45 for specific statistical power values, i.e. 50%, 
60%, 80% and 90%.  These curves were determined using a two-sided t-test with two 
independent samples, thus, our values of  1 and  45 were compared against the null 
hypothesis, Ho: RRR = 1.  The results of this analysis as it relates to our project goal of 
achieving 80% power is shown in Figure 25 below.   
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Figure 25.  Effect of DMA vs.  DCE on sample size 
 (a) Plot of sample sizes when 80% power is achieved for a population characterized by our  
values of RRRMA and RRRCE  (1 =  0.052, standard deviation for RRRMA  =  0.014,     
45  =  0.087, standard deviation for RRRCE  =  0.021). The red circle indicates the region on 
the graph that is not limited by concerns of equipoise due to low RRR values or lack of 
descriptive statistics due to low sample sizes. 
 
(b) The region within the red circle in figure (a) 
is enlarged and demonstrates the relationship between RRR values and sample size when RRR 
is calculated using DMA vs. DCE.  The orange arrows indicate the sample sizes for RRRMA and 
RRRCE at RRR  =  0.986 (48 vs. 22 patients) and RRR  =  0.984 (17 vs. 37 patients). 
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 Figure 25a demonstrates the relationship between sample size and RRRMA or RRRCE 
when 80% statistical power was achieved.   The curves for RRRMA or RRRCE were 
characterized using values from our patient sample (N = 18), i.e., 1, 45, and values 
of  experimental standard deviations of  RRRMA and RRRCE, respectfully.    In addition, Figure 
25 demonstrates the effect of factors which limit the intervals of acceptable sample size and 
RRR, i.e., the number of subjects required to achieve descriptive statistics and the range of RRR 
in which concerns regarding equipoise are avoided.  When the aforementioned limitations are 
addressed, the intervals of acceptable sample size and the RRR shrank (Figure 25b).  Within 
that window, we found that for 80% power and a RRR value of 0.984, 37 patients vs. 17 were 
needed if RRR is calculated using DCE vs. DMA.  For a RRR value of 0.986, 48 patients vs. 22 
were needed if RRR is calculated using DCE vs. DMA.   
 
3.5.1 Four factors that affect sample size  
To further understand the interplay between estimates for RRR and sample size, we 
used PS to estimate sample size for three general relationships.  In particular, we followed a 
procedure similar to the one used to create Figure 25 to illustrate the influence of (1) power, (2) 
variance (or standard deviation), and (3) α on sample size using data from the virtual clinical 
trial.  Thus, our estimations for sample size probed the impact of differing values of power, 
variance (or standard deviation), and α for two populations, i.e., one characterized by our 
values of RRRMA, and one characterized by our values of, RRRCE (Figures 26-28).  The 
corresponding input parameters for these three tests are listed in Table 22 below. 
 
Table 22.  Input parameters for estimates of sample size relative to differing values for 
power (1-β), standard deviation of RRR (σRRR), and α. 
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  Figure 26 represents our first generalized estimation.  That is, it compares the effect of 
differing values for power on sample size. 
 
Figure 26.  Effect of power on sample size 
Sample size is plotted against RRR for two populations (input parameters in Table 22).  In one 
population (solid lines), RRR was calculated using DCE, i.e., RRRCE, and in the other (dashed 
lines) RRR was calculated using DMA, i.e., RRRMA.  Power curves are shown in solid lines for 
RRRCE vs. sample size and in dashed lines for RRRMA vs. sample size.  Alpha was set to 5% for 
all curves. 
 
Figure 26 demonstrates that in order to achieve 50% to 90% power, a larger sample size is 
required when DCE is used to estimate RRR.  It also shows that the difference in sample sizes is 
most applicable when small samples are used, i.e., sample sizes of 5 or less.  This finding is 
expanded upon in Table 23 (below) which presents an analysis based on data from Figure 26.  
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Table 23. Effect of power on sample size for RRRMA vs. RRRCE 
Values for the absolute difference and the percent absolute difference between RRRMA and 
RRRCE are shown for the 80% and 50% power curves at specific sample sizes. 
 
 
Table 23 highlights the result that use of DMA vs. DCE when estimating RRR has a more 
notable difference at the level of individual comparisons of risk for an individual patient, i.e., 
as opposed to a sample of patients.  In other words, estimates of RRR
 
differed by as much as 
19% when RRRCE  was used in place of RRR MA in a case study (sample size of 1) or 4% when 
a sample size of 2 is used.  When the sample size increases beyond 5, the percent difference in 
estimates for RRRMA vs. RRRCE drops to less than 1%.    
To further investigate use of RRRMA vs. RRRCE, we focused on the potential impact of 
differences in standard deviation on sample size.  Recall that in our virtual clinical trial, the 
experimental standard deviation was 0.014 for RRRMA and 0.021 for RRRCE .  Figure 27 plots 
the impact of the standard deviation on sample size. 
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Figure 27.  Effect of standard deviation on sample size 
Curves for estimations of the RRR are plotted against sample size for 80% power and an alpha 
value of 0.05.  In (a) and (b) curves are shown for the cases in which the standard deviations of 
estimates for RRR are 0.05, 0.03, 0.02, and 0.01.  In (a) the general shape of the plot is shown.  
Enlarged images of the relationship between curves for (b) sample sizes less than 5 and (c) 
sample sizes larger than 15 are shown.  Also in (c) standard deviations from the virtual clinical 
trial were added (dashed lines).  Data for standard deviations of 0.01. 0.014, and 0.02 were not 
available for sample sizes less than 16, 32, and 64, respectively.   
 
In Figures 27a and 27b, we see that with smaller standard deviations, fewer samples are 
needed to achieve 80% power and a 5% alpha value.  In Figure 27c we see an application of 
this concept within the frame work of our virtual clinical trial because curves which represent 
the experimental standard deviation from our clinical trial are shown.  Additionally in Figure 
27c, the curves for standard deviation are shown within the window of sample size values that 
is not limited by a lack of equipoise or descriptive statistics (Figure 27c).  From Figure 27c, we 
see that there can be a very subtle affect of standard deviation on sample size and that it is most 
pronounced at values of RRR which approach unity.  More specifically in a comparison of the 
curves for standard deviation values: 0.020 vs. 0.021, there is a maximum difference of 6 in 
sample size at RRR = 0.99.   
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Figure 28 plots the effect of differing alpha values (α) on estimations for sample size, 
i.e., each α corresponded to differing probabilities of Type I errors which impacted the required 
sample size.4 
 
 
Figure 28. Effect of alpha on sample size 
Curves for varying alpha values are shown in solid lines for RRRCE vs. sample size and in 
dashed lines for RRRMA vs. sample size.  Input parameters were given in Table 22.  In (a) the 
general shape of the plot is shown.  Enlarged images are shown for (b) sample sizes less than 5 
and (c) sample sizes larger than 5.   
 
In Figure 28, we see that larger alpha values correspond with smaller sample sizes.  We 
also see in Figures 28a and 28b that at sample sizes less than 5 there is a potential for overlap in 
curves which are characterized by different input parameters, i.e., in the region of RRR = 0.6 to 
RRR = 0.8, the curve for an alpha value of 0.02 for the population characterized by input from 
RRRMA crosses several alpha curves (alpha = 0.05, 0.06, and 0.08) belonging the population 
characterized by input from RRRCE.  However when the plot is limited to a range of RRR and 
sample size that satisfy the need for equipoise and descriptive statistics, as in Figure 28c, there 
                                                     
4
 Type I errors represented errors associated with the assumption that for our sample there was no difference in 
predicted risk between proton and photon CSI when, in reality, a larger population would show a difference in 
predicted risk between proton and photon CSI.  
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is no chance for overlap between curves.  Thus, as expected, Figure 28 demonstrates that the 
potential for introducing a Type I error is reduced at higher sample sizes.   
 
3.6 Uncertainty analysis  
To estimate uncertainty in RRR when DCE and DMA are respectively used, we performed 
uncertainty analysis for the predominant factors which contributed to uncertainty in RRR.  Our 
analysis of uncertainty in absorbed dose, the cell sterilization factor, and the neutron weighting 
factor, are presented in sections 3.5.1, 3.5.2, and 3.5.3, respectively.   In section 3.5.4, we 
combine the data from sections 3.5.1 - 3.5.3 to estimate the corresponding uncertainty in RRR 
when DCE and DMA were respectively used.   Finally in section 3.5.5, we estimated the impact 
of uncertainty in RRR on sample size.   
3.6.1 Uncertainty in absorbed dose 
  In this section we present the results of our estimation of uncertainty in absorbed dose 
in the thyroid due to variations in patient-set up for proton vs. photon CSI.   More specifically, 
we estimated the mean dose in the thyroid when it was shifted relative to its original position, 
i.e., its location at the time of treatment planning.  Shifts on the order of 0.5 cm were made in 
the superior, inferior, anterior, posterior, right, and left directions.  An illustration of the 
anterior and posterior shifts is shown below in Figure 29. 
  
Figure 29.  Thyroid location relative to the treatment field for proton and photon CSI 
The original position of the thyroid (pink) is shown for a 10 year-old female.  Also shown are 
its positions when shifted by 0.5 cm superiorly (light green) or inferiorly (dark green).  The 
beam direction is indicated by a yellow arrow, and dose distributions are shown in color wash.  
In (a) the dose distribution is shown for photon CSI, and in (b) the dose distribution is shown 
for proton CSI.  In both images dose is shown in units of cGy (RBE) where RBE is set to 1.1 
for proton CSI and 1 for photon CSI.  
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From Figure 29, we see that shifts in thyroid location in the anterior – posterior direction may 
potentially impact the mean absorbed dose in the thyroid; however, we also see that shifts in 
specific directions may have more impact than others.   Quantitative results for the mean 
absorbed dose in each shifted location are presented in Table 24 below. 
 
Table 24.  Absorbed dose and summary statistics for shifts in the thyroid location relative 
to the original treatment field 
 
 
From Table 24, we see that shifts in the posterior direction corresponded with the 
largest change in mean absorbed dose for both proton and photon CSI.  More specifically, the 
estimated interval in absorbed dose values due to 0.5 cm shifts in the thyroid location was 39.3 
cGy (RBE) and 39.8 cGy (RBE) for proton CSI when DCE and DMA are respectively applied, 
and for photon CSI the estimated intervals are 44.1 cGy and 198.2 cGy when DCE  and DMA 
were respectively applied.   These intervals represent to our estimated uncertainty in absorbed 
dose due to variations in patient set-up, or our value for 
XD
σ in Equation 2.25.  As a result, 
when we took a ratio of the our values of 
XD
σ and the mean absorbed dose in the case of no 
shifts, 1.4 cGy (RBE) for proton CSI and 1001.9 cGy or 1836.7 cGy for photon CSI when DCE  
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or DMA  were respectively applied, our values of
X
X
D
Dσ in Equation 2.25 were 28.0 or 28.4 for 
proton CSI when X = CE or MA and 0.044 or 0.018 for photon CSI when X = CE or MA.  
These findings support our earlier observations (see Figure15) which demonstrated that proton 
CSI is highly sensitive to fluctuations in thyroid dose.   
3.6.2 Uncertainty in the cell sterilization  factor 
We estimated uncertainty in the cell sterilization factor, σC, by determining its interval 
when values for the thyroid-specific cell sterilization factor, α (Equation 2.27) are varied.  To 
visualize the effect of variations in α on C, we plotted a range of absorbed dose values, D (Gy), 
against the corresponding cancer equivalent dose, DCE (Gy).  This was done for the minimum 
value for α (Equation 2.26), αMIN; the value for α that was used in this study, α*; and the 
maximum value for α (Equation 2.26), αMAX; i.e., we plotted D (Gy) vs. D (Gy)* C(D,α) 
(Figure 30). 
 
Figure 30.  DCE  with various correction factors 
Absorbed dose, D (Gy), was plotted against a several curves for cancer equivalent dose, DCE 
(Gy).   The red curve represents the case where the minimum value for α was applied, i.e., C(D, 
α  =  0.020).  The blue curve represents the case where the value for α that was used in this 
study was applied, i.e., C(D, α  =  0.033).  The green curve represents the case where the 
maximum value for α was applied, i.e., C(D, α  =  0.047).  Inflection points for the curves 
occur at 50 Gy, 30 Gy, and 21 Gy, respectively.  The dashed lines show the locations of the 
study’s mean values of absorbed dose in the thyroid from proton CSI (Table 7) and photon CSI 
(Table 8).  
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In Figure 30, we found, that for absorbed dose values which are less than 7.5 Gy, there 
was little sensitivity to variation in α, but for absorbed dose greater than 10 Gy there is greater 
sensitivity.  This provides a visual demonstration of what previous sections revealed: the larger 
values of absorbed dose from photon CSI are more sensitive to the cell sterilization factor than 
the smaller values from proton CSI.  We also found that the curves for DCE had inflection 
points at 50 Gy, 30 Gy, and 21 Gy for αMIN, α*, and αMAX, respectively.    The location of our 
inflection point for α* agrees with the results of Sigurdson et al (2005) in which the inflection 
point for observing cell sterilization in the thyroid was observed at 30 Gy.  This agreement 
supported our use of 0.033 for α in the study; however to determine the potential uncertainty in 
our estimates, we used the minimum and maximum values of α to determine the maximum 
interval for C (Equation 2.29).  Our results for proton and photon CSI are found in Table 25 
below. 
 
Table 25.  Uncertainty estimates for cell sterilization  
In the first three columns values are reported for mean absorbed dose from the TPS, D , stray 
dose from neutrons, Hstray, and the total effective dose, Htotal, for a 10 year-old female (patient # 
14) receiving 23.4 Gy (RBE) from proton vs. photon CSI where the RBE values are 1.1 and 1, 
respectively.  In the next three columns, values are listed for the thyroid-specific cell 
sterilization factor, α, i.e. the minimum value for α, the value for α that was used in this study 
(α*), and the maximum value for α; the corresponding correction factors, C; and the 
corresponding values of cancer equivalent dose, HCE.  Finally in the last two columns, we 
present the interval for C, Cσ , and 
*
C
Cσ
,
 
where
 C* is the value of C when α* is used. 
 
 
3.6.3 Uncertainty in the mean radiation weighing factor for neutrons 
 We estimated uncertainty in Rw by scaling our values of Rw  by 0.5 and 2 and 
applying those values to our estimates for RRRX where X = MA or CE.  We then used these the 
scaled values of RRRX to determine a representative bracket of uncertainty for Rw .  Results 
for this process are shown in Table 26 below. 
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Table 26.  Uncertainty in the mean radiation weighting factor for neutrons 
 
  
Table 26 reveals that scaling Rw did have an impact on our estimates for RRRMA  and 
RRRCE, and as a result, our estimates for uncertainty in Rw differed accordingly.  More 
specifically uncertainty in  Rw  was 24% less when DMA was applied to our estimates for RRR 
than or when the DCE was applied.  Nonetheless, when these respective values of uncertainty 
were divided by the mean value for Rw  across all treatment fields (7.93 from Table 5), the 
distinction between use of DMA vs. DCE was reduced.  In particular, the relative uncertainty in 
Rw  was approximately 0.01, regardless of its method of estimation. 
3.6.4 Uncertainty in RRR when DCE vs. DMA are used 
 Once the results from the individual uncertainty analyses, i.e., the uncertainty analyses 
for absorbed dose, cell sterilization, and the neutron weighting factor, were combined  
(Equation 2.25), we determined their combined uncertainty through our estimates of  RRR 
(Equation 2.24).  Results of this analysis are listed in Table 27 below. 
 
 
Table 27.  Estimates of relative uncertainty in RRR when DCE vs. DMA are used 
Values are listed for the terms in Equations 2.24 and 2.25 which are used to estimate relative 
uncertainty in RRRMA  and RRRCE.  Entries for 
*C
Cσ
are blank when DMA was used because a 
cell sterilization factor was not applied in that case.  Also, the entry for XOYOY  is blank for photon 
CSI because the mean radiation weighting factor for neutrons did not apply. 
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 Table 27 reveals that relative uncertainty in RRR is approximately the same regardless 
of when DCE was applied or when DMA was applied, i.e., the percent difference between  
and  is less than 1%.  This stems from the finding that uncertainty in RRR is largely 
dominated by relative uncertainty in absorbed dose, namely the uncertainty in absorbed dose 
from proton CSI.  Moreover, the disproportionately large values of 
x
X
D
Dσ
from proton CSI vs. 
photon CSI indicate that the predicted risk of SC in the thyroid from proton CSI is notably 
more patient-specific than that of photon CSI.  Additionally, with large values of 
x
X
D
Dσ
, 
uncertainty in predicted risk for adjacent organs is increased.  
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Chapter Four 
 
4 Discussion 
We used a virtual clinical trial to determine the impact of cell sterilization effects on 
estimations of the relative risk for a second cancer in the thyroid following proton vs. photon 
CSI.  Our goal was to determine if use of DCE would reduce the sample size needed to achieve 
80% power.  However, data from our virtual trial revealed that achieving 80% statistical power 
(with an alpha value of 0.05) required a maximum sample size of 1 patient.  Because this 
finding occurred regardless of whether DCE or DMA was used, it highlighted several important 
trends in our data.  In particular, it confirmed that the predicted risk of second cancer in the 
thyroid is greater after CSI with photons vs. protons.  Accordingly, because the predicted risk 
increased with the equivalent dose in the thyroid, use of DCE reduced total equivalent dose for 
photon CSI by approximately 44%, and while the total equivalent dose in proton CSI was 
generally insensitive to DCE,we did find that in one patient the use of DCE reduced total 
equivalent dose for proton CSI by as much as 22%.  This revealed the potential importance of 
patient-specific analysis for proton CSI and hints that the greatest factor contributing to 
uncertainty in our estimates for RRR was uncertainty in the absorbed dose from proton CSI.  
Additionally, this work we analyzed risk in a population of patients (N = 18) and studied the 
influence of power, experimental standard deviation, and alpha values on required sample size.   
Also, this work highlighted the potential impact of cell sterilization factors on future clinical 
trial design.  More specifically, it revealed that sample size can increase with the use of a cell 
sterilization factor and that failure to account for this can lead to trial designs that will have 
larger than expected probabilities of Type II and Type I errors.  This is important because it can 
have clinical repercussions with respect to the additional resources and time that would be 
required to acquire additional patients.  This is particularly relevant in the case of rare cancers 
in small populations. 
4.1 Previous literature  
 When compared to previous works, this study is unique in its application of dosimetic 
metrics.  Specifically, this study is the first to apply a cell sterilization factor to a population of 
patients in which estimates for second cancer risk are based on patient-specific estimates of 
stray and therapeutic dose.  As a result, we are unable to make direct comparisons of our 
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estimates for second cancer risk with previous works, but we were able to compare specific 
aspects of our results with those previous works, specifically those of Newhauser et al. (2009) 
and Brodin et al. (2011).     
In their work, Newhauser et al. considered the risk of second cancer of the thyroid from 
therapeutic and stray radiation in the case of pediatric CSI as we did.  In particular, Newhauser 
et al. estimated lifetime attributable risk following the recommendations of ICRP Publication 
60 (1990) and they reported that the predicted lifetime risk of developing a second cancer of 
the thyroid at 0.35%.  In this work, we estimated RR following the recommendations in the 
report of the BEIR VII Committee (NRC 2006).  Our estimates of stray dose, 437 mSv, are in 
good agreement with those of Newhauser et al, 443 mSv. Newhauser et al. (2009) used the 
therapeutic absorbed dose from Miralbell et al. (2002), and we used therapeutic doses which 
were calculated specifically for each patient in our study.  As a result of the differing strategies 
for determining therapeutic dose, the study by Newhauser et al. (2009), which took therapeutic 
dose from Miralbell et al., reported that therapeutic dose was the greatest contributing factor to 
the risk of second cancers in the thyroid, and our study reports that stray dose is the greatest 
contributing factor.   Nonetheless, the fact that our findings for dose from stray radiation agree 
within 1.3%, provides some external validation of our results. 
 Our study was also similar to that of Brodin et al. (2011) in that they, too, considered 
the contribution of stray and therapeutic dose in their estimates of second cancer risk in the 
thyroid.  Additionally, they considered a cell sterilization factor for dose, as we did.  However, 
they chose to follow a different dose-response model than we did to account for cell 
sterilization.  Specifically, they chose a linear plateau-model while we selected a linear 
exponential model.  Additionally, their study focused on different methods of radiation delivery 
than ours did.  They studied the effects of rotational intensity modulated radiation therapy with 
photons (rotational IMRT), conventional 3D radiation therapy with photons (3D CRT), and 
intensity modulated radiation therapy with protons (IMPT).  Because they took values of dose 
from stray radiation in IMPT from Newhauser et al. (2009), our results for dose from stray 
radiation agreed with theirs.  However, they used a different model for predicting risk than we 
did.  Specifically they estimated excess absolute risk following the method of Schneider et al. 
(2008) which takes into account attainted age, sex, and age at exposure while we estimated 
excess relative risk using BEIR VII (NRC 2006) which takes sex, age at exposure and organ 
specific factors into account.  Thus, the main difference in these estimates is that Brodin et al. 
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(2011) used data from the Life Span Study (UNSCEAR 2000) and a weighted mean approach 
to estimate thyroid specific results, and at the dose levels of our project, any resulting 
differences in the respective estimations of risk were considered negligible. 
 In an attempt to compare one additional aspect of our study to previous works, namely 
the effect of using a cell sterilization  factor we surveyed several works which address this 
topic (Brodin et al. 2011, Bhatti et al. 2010, Schneider et al. 2005, Ronckers et al. 2005, and 
Sigurdson et al. 2005).  This revealed no overall consensus regarding which model is most the 
appropriate model to use for pediatric CSI patients.  In particular, Brodin et al. (2011) used data 
from Schneider et al. (2008) to compare the linear, linear-exponential, and plateau dose-
response models.  Their finding was that the plateau dose-response model provided the best fit.  
Because, they did not provide all the parameters used in their analysis, we did not make a direct 
comparison with the model used in this work.  For our remaining comparisons, we plotted dose 
response curves from Sigurdson et al. (2005), Ronckers et al. (2005), Schneider et al. (2006), 
and Bhatia et al. (2010) in Figure 31 below.   
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Figure 31. Comparison of dose-response models 
Relative risk is plotted against absorbed dose for several dose-response models in the literature.  
The model used in this study is the linear exponential from Schneider et al. (2005) with a 
thyroid-specific cell sterilization parameter of 0.033 (dashed navy blue curve).  In (a) the dose 
response models are shown for high and low dose regions.  In (b) the dose response models are 
shown to the maximum therapeutic dose, including boost, that would be delivered for a 
population of pediatric patients being treated with CSI.  The yellow boxes in both images 
represent the area which corresponds to the interval of therapeutic dose in this study, 0 Gy to 
25 Gy. 
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 The dose-response model that we used to estimate DCE was based on the work of 
Schneider et al. (2006) in which they determined that a linear exponential model provided the 
best fit to their data.  Also in their work, they provided a 95% confidence interval for their 
exponential term.  We graphed these and used them as a lower and upper bound estimate for 
the linear exponential used in our work (Figure 31).  Additional works which based their 
analysis on data from the Childhood Cancer Survivorship Study (CCSS) included that of 
Ronckers et al. (2005) which examined several curves.  The best fit was achieved with a linear 
exponential quadratic model (Figure 31).  In the work by Sigurdson et al. (2005), they report 
that a linear exponential curve affords the best fit (Figure 31), however, when graphed this 
curve overlies the linear exponential quadratic defined by Ronckers et al. (2005).  In an update 
to the CCSS study by Bhatti et al. (2010), the dose-response curve from Sigurdson et al. (2005) 
was updated to a new linear exponential quadratic (Figure 31) which more closely resembles 
the a linear exponential curves from Schneider et al. (2005).  In particular, it resembles the 
lower-bound estimate from Schneider et al. (2005).  Thus, through comparison with these 
previous works, we found that use of the cell sterilization factor provided by Schneider et al. 
(2006) provides a comparatively conservative estimate of risk (Figure 31b).  This is a 
particularly important finding when one considers that studies such as ours may be used in 
clinical decision making.   
 
4.2 Major findings and implications 
 One of the major findings from this work is that for a sample of patients receiving CSI, 
DCE made only a 2.5% difference in predicted estimates for RRR.  However, on a patient-by-
patient basis use of  DCE made as much as an 11% difference in estimates of RRR for an 
individual patient.  Because the patient with an 11% difference, patient 1,  was subjected to the 
same SOC and physician approval criteria as the other patients in the sample, this finding has 
two potential implications.  The first implication is that predicted risk can be very patient 
specific, particularly in the case of proton CSI.  Reasons for this include a potential for errors in 
range and patient set-up.  This suggests that it may be more prudent to perform personalized 
risk estimates on a per-patient-basis, i.e., class estimates for risk, at least within our population 
could have resulted in an 11% error in risk.   A second implication is that regions of higher 
dose may be more sensitive to the cell sterilization effect.  In particular, there may be 
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implication with respect to regions that are subject to higher dose gradients or regions in which 
there is a higher potential for dose irregularities, i.e., in structures that move, such as the lung 
or heart.   
 An additional finding of this work was that as the value of RRR  approaches one, i.e., 
when RRR  > 0.8, calculations of sample size become increasingly important and sensitive to 
factors such as the experimental standard deviations of the respective populations.  In other 
words, when there is a less than 20% difference in the estimates for risk from proton vs. photon 
CSI, a larger population of patients is needed in order to confidently determine if a difference 
in risk exists.   While this is an expected result, we were surprised at the magnitude of the 
difference in sample size in relation to shifts in standard deviation.  More specifically, we 
found a 6 patient difference for a change in experimental standard deviation of 0.001 (Figure 
27c) which can have profound implications with respect to resources and the required time for 
studies in which eligible patient pool is limited, as is the case in pediatric populations.    
 Finally, we found that application of a cell sterilization factor, DCE, increased the 
experimental standard deviation of our population.  As a result, when DCE was applied to our 
population, our estimate of RRR  was more susceptible to Type I and Type II errors and 
required larger sample sizes (Figures 26, 28).  Thus, while the exact numerical impact of a cell 
sterilization factor may differ with the specific dose-response model that is selected (Figure 
31), our study shows that when a cell sterilization factor is taken into account, it can impact 
sample size.  Thus, without careful consideration a higher probability of statistical error can be 
introduced (Schafer and Gilbert 2006).  Moreover, when we consider the dose range of this 
study, the actual dose-response model becomes less important, because the models differ most 
in the high dose region.  It is the low dose region which applies most to pediatric populations 
and accordingly has the greatest potential to effect clinical decision making. 
 
4.3 Study strengths 
This project is one of the first population-based virtual studies of comparative risk that 
departs from the traditional use of DMA.  To our knowledge it is the only study that explores the 
relationship between cell sterilization and statistical significance in an epidemiological study of 
small sample groups, e.g., groups which include pediatric cancers and patients treated with 
advanced radiotherapy.  Additionally, no prior study has applied similar concepts to a 
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population in which both therapeutic and stray dose were determined on a patient-specific 
basis.   Thus, the major strength of this work is that it revealed the potential impact of cell 
sterilization factors on sample size in small-scale radio-epidemiological studies.  Additionally, 
it provides the first general analysis of what sample sizes are needed to meet the dual 
requirements of equipoise and descriptive statistics.   
 
4.4 Study limitations  
There were several limitations to our study.  For clarity we have grouped them into two 
general categories:  those related to the design of the virtual clinical trial and those which are 
model specific.  With respect to the design of the virtual clinical trial, we have defined three 
potential limitations.  In the first of these, we note that we used a mean radiation weighting 
factor for neutrons which was generalized for our patient population.  Ideally the neutron 
weighting factor would be determined on a patient-specific basis; however, given the time 
constraints for this work and the fact that field energies varied little between patients, this was 
not a serious limitation.  A second limitation, related to trial design, was that we considered 
only one organ.   In particular, we performed our risk analysis on the thyroid which is small, of 
fairly constant density, and did not display large gradient of dose in our treatment plans. As a 
result, our study had little dosimetric variation which resulted in small standard deviations in 
dose i.e., the experimental standard deviation for Htotal was less than 8.5% for proton CSI and 
less than 5.5% for photon CSI.  While this limited the applicability of our risk analysis to other 
organs with greater tissue heterogeneity, it also provided a solid first step in our investigation 
of the effect of a factor for cell sterilization because the thyroid is one of the organs with the 
greatest known effect (Bhatti et al. 2011).   Thus, by focusing on the thyroid we were able to 
limit the potential for competing variables in our study.  Finally, we did not include results 
from intensity modulated photon therapy, IMRT.  In this respect, use of IMRT may have 
introduced a CSI technique for photons with tissue sparing that was more comparable to that of 
CSI with passively scattered protons.  This may have increased our values of RRR which may 
have impacted our findings regarding sample size when DCE vs. DMA were applied.  However, 
because IMRT is not the SOC for CSI, we are confident that our use of the FIF technique for 
photon CSI may ultimately yield the most clinically relevant results.    
With respect to the model specific limitations of our study, we have also defined three 
potential limiting factors, the first of which deals with our choice for the thyroid specific cell 
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sterilization factor alpha, α.  In our work we used estimates for α which were determined by 
Schneider et al. (2006) with data from Hodgkin’s patients.   As noted in our uncertainty 
analysis (section 2.10.2), there are some conflicting reports in the literature regarding whether 
or not cell-sterilization occurs similarly for Hodgkin’s patients vs. non-Hodgkin’s patients 
(Sigurdson et al. 2005; Ronckers et al. 2006).  Moreover the region of low doses, such as was 
used in our study, is the region in which the differences are greatest between the dose-response 
curves suggested by Sigurdson et al., Ronckers et al., and Schneider et al. (Figure 31).  As a 
result, we agree that this could be a very notable limitation in our work.  However, in light of 
our results for uncertainty in RRR, i.e., the two major contributors to relative uncertainty in 
RRR are uncertainty in absorbed dose for proton CSI, on the order of 2800%, vs. relative 
uncertainty in the cell sterilization factor, on the order of 50%.  We remain confident that 
uncertainty in the thyroid-specific cell sterilization factor does not invalidate our results and, 
indeed, was the impetus for much of the uncertainty analysis in this work.  In a second 
limitation stemming from the dose-response model, we note that the model used in this work, 
the BEIR VII model for ERR/H does not take dose fractionation into account.  Moreover, the 
BEIR VII data is based on A-bomb survivor data and because risk is not linear with dose, linear 
adaptations of the BEIR VII data to our region of low dose, is not optimal.  However, until 
more data is available, use of the BEIR VII model represents a reasonable choice.  Finally, a 
third limitation, which is associated with the dose-response model, is that while radiation 
therapy (RT) accounts for roughly 8% of second cancers in adults other factors such as 
lifestyle, environmental factors and genetic susceptibility may account for more than 90% of 
the remaining occurrences of second cancers (Berrington de Gonzalez et al. 2011).   This is a 
limitation because current models do not describe how RT interacts with the aforementioned 
other factors.  However, this is an active area of research (Morton and Chanock 2011), so when 
results become available, the results from our study can be adjusted in a straightforward 
manner.  In this respect, this limitation may be overcome in a future work. 
 
4.5 Future work 
Given the biological and statistical complexity of this subject, future studies are needed 
to determine the effect of DCE vs. DMA in other organs.  This includes organs with differing 
tissue heterogeneity, organs which move, and organs which receive partial in-field irradiation.  
Additionally, in an effort to address the uncertainty associated with the selection of appropriate 
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dose-response models, efforts to retrospectively compare the results of this study with actual 
patient outcomes would be greatly beneficial.  Such work may be particularly challenging in 
the case of proton CSI given the relative rarity of pediatric cancer and the historically limited 
availability of proton therapy.   However, this constraint is fading.  There are approximately 28 
proton therapy centers in operation world-wide (Particle Therapy Co-Operative Group, 2010); 
thus, there is a growing potential for creating a database of treatment outcomes which would 
facilitate retrospective comparisons.   
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Chapter Five 
5 Conclusions 
This work was motivated by the unique challenges associated with epidemiological 
studies of late effects from contemporary radiation therapy.  First, the risk of developing a 
radiation-related second cancer increases with the time since exposure, and the latency for solid 
tumors is 5 years or more.  Thus, by the time a study can be completed, the contemporary 
treatment is no longer contemporary.  Second, while second cancers account for 18% of cancer 
diagnoses (Howlander et al. 2011), it is still difficult to accrue sufficient numbers of patients 
for a population based outcome study.  This challenge is compounded when rare sub-groups, 
such as patients who received pediatric radiation are considered.  Third, the traditional 
approach of estimating second cancers from radiation organ dose considers only mean organ 
dose.  This approach overlooks the effect of cell sterilization which at high doses makes second 
cancer formation unlikely.   In our work, we used a prospective method to compare and predict 
the risk of radiation related second cancers for different contemporary radiation therapy 
techniques, i.e., a virtual clinical trial.  We tested this method for a recurring challenge in radio-
epidemiological studies, small sample sizes.  As a result, we considered (1) a rare pediatric 
cancer requiring craniospinal irradiation and (2) a rare but well understood second cancer, 
thyroid cancer.  We considered the effect cell sterilization on risk prediction and, consequently, 
sample size in a micro-clinical trial.  As a result, we found that in a trial of radiation therapy 
techniques, when the difference in the predicted risk of second cancers is less than 10%, 
inclusion of cell sterilization in the dose model results in a need for larger sample sizes if a 
study is designed to achieve 80% statistical power.   
This work demonstrated that it is possible to prospectively evaluate contemporary 
radiation therapy techniques for radiation-related second cancers using a virtual clinical trial 
approach.  This work provided specific results which indicate that these types of studies can 
achieve statistical significance, even with small sample sizes.  Specifically, the required sample 
size (N) for our specific study was unity, regardless of whether cell sterilization was included 
in the dose model.  Reasons for this include relatively large differences in absorbed dose in the 
thyroid from proton vs. photon CSI (1 = 0.052, 45 = 0.087) and small variations in 
absorbed dose across the patient sample due to small variations in patient anatomy relative to 
the treatment field (NZ[= 0.014, N\]= 0.021). Additionally, this work found that for 
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proton CSI there is potential for increased variation in patient specific risk estimates, up to a 
factor of 27, when error in patient set-up is considered.  Thus, in that case or others, when there 
is increased variation in patient specific risk estimates (σRRR) or when the difference in the 
predicted risk of second cancers is less than 10%, using alternate concepts for dose, i.e., use of 
cell sterilization rather than mean organ dose can greatly impact estimations for sample size.  
Furthermore, this study revealed that accurate estimation sample size may be vitally important 
to avoid statistical error.  However, using alternate concepts for dose requires careful study 
design because the outcome is very sensitive to the factors used in the cell sterilization model.  
Ignoring or selecting wrong factors can result in under-sampling, which can have profound 
implications on the quality or even the validity of study results.     Thus, we conclude that 
patient specific studies are the most appropriate types of studies for clinical decision making as 
statistical averaging may overestimate the errors for some individuals.  This is especially true 
for proton therapy where range and set-up error dramatically impact organ dose.   Moreover, it 
is especially important that the details of the treatment plans and their uncertainties be given 
careful consideration when comparing different treatment techniques because the details can 
change the outcome of the study.   
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